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A.1 Mammalian Membranous Adenylyl Cyclases 
A.1.1 The cAMP Signaling Pathway 
Over 50 years ago Sutherland and Rall (Berthet et al., 1957a; Berthet et al., 
1957b) discovered the role of cyclic adenosine 3’,5’-monophosphate (cAMP) in 
biological effects (Sutherland, 1972). cAMP is one of the various small molecules 
referred to as “second messenger” that relay signals form receptors on the cell 
surface to target molecules inside the cell. The concept of second messenger 
signaling is now well established. The second messenger pathways concerning G 
proteins as transducers arose to one of the best studied of the cell surface signal 
transduction pathways. The effects of cAMP as second messenger are broad and 
often very complex. One of the key roles is its influence during cell development, e.g. 
by modulation of the progression within the cell cycle (Hanoune and Defer, 2001), the 
regulation of gene transcription (Rodbell, 1980) and its growth-stimulatory effect 
(Dumont et al., 1989). The second messenger molecule is also involved in blood 
coagulation (Steer and Salzman, 1980), neuronal function (Kebabian, 1977) and the 
control of immune (Parker et al., 1974) and visual responses (Bitensky et al., 1971). 
This diversity of regulatory features is closely related to the variety of potential 
regulators of cAMP synthesis and degradation (Hanoune and Defer, 2001).  
Adenylyl cyclases (ACs) are integral membrane proteins which catalyze the 
conversion from ATP to cAMP (Ishikawa and Homcy, 1997; Hurley, 1998) (Fig. A.1). 
Activation of these effector proteins transfers signals from the extracellular to the 
cytosolic side (Cooper et al., 1995; Defer et al., 2000) and contributes to cross-talks 
in different cell systems and signaling structures (Iyengar, 1993; Sunahara et al., 
1996).  
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Fig. A.1. Adenylyl cyclase reaction. AC catalyzes the conversion of ATP into cAMP 
and pyrophosphate. The resulting amount of cAMP is measured as an indicator of 
enzyme activity.  
Chapter 1: General Introduction in Mammalian Membranous Adenylyl Cyclases 
 
3 
Neurotransmitters, hormones, odorants and autacoids act as first messenger 
molecules via activation of G protein-coupled receptors (GPCRs). GPCRs are cell 
membrane proteins consisting of seven hydrophobic transmembrane segments, an 
extracellular amino terminus and an intracellular carboxyl terminus (Kolakowski, 
1994; Palczewski et al., 2000). Having identified over 800 members of GPCRs, they 
are the largest family in the human genome (Kobilka, 2007). These receptors 
communicate with heterotrimeric, membrane-associated G proteins, which in turn 
activate ACs. G proteins can be divided into a Gα subunit, associated with guanosine 
5’-diphosphate (GDP) in the inactive state and a Gβγ heterodimer. Receptor activation 
leads to the release of GDP and its replacement by GTP. Subsequently, a 
conformational change induces the dissociation of GTP-bound Gα subunit from the 
Gβγ dimer. ACs can be modulated by the free Gα subunit, either in a stimulatory (GSα 
family) or in an inhibitory (Giα family) way (Gilman, 1987; Iyengar, 1993; Kristiansen, 
2004). The active state of Gα is terminated by its GTPase activity, which means the 
cleavage of GTP into GDP and inorganic phosphate (Pi), and its reassociation with 
Gβγ.  
Furthermore, cAMP activates cyclic nucleotide-gated ion channels or directly 
interacts with protein kinase A (PKA) promoting further phosphorylation steps (Defer 
et al., 2000). In turn, PKA activation is involved in cell growth, metabolism, 
differentiation and transcriptional regulation (Wing and Robinson, 1968; Rodbell, 
1980; Dumont et al., 1989). Without any phosphorylation, cAMP can also prompt 
protein-protein interactions, e.g. in signaling of Rap1 proteins (Kawasaki et al., 1998).  
Second messenger signaling is terminated by the degradation of cAMP. Cyclic 
nucleotide phosphodiesterases (PDEs) break the phosphodiester bond of cAMP and 
therefore regulate the localization, duration, and amplitude of cyclic nucleotide 
signaling within subcellular domains.  
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A.1.2 Structure and Catalytic Mechanism of Mammalian ACs 
Using analysis of amino acid sequences and molecular cloning techniques, 
nine mammalian membrane-bound AC isoforms have been identified so far. These 
ACs are integral glycoproteins with a calculated molecular weight of 119 to 175 kDa. 
They share a considerable degree of sequence homology in their primary and tertiary 
structure (Tang and Gilman, 1992; Yan et al., 1996; Tang and Hurley, 1998). Fig. A.2 
shows the proposed structure of membrane-bound ACs. The short variable amino-
terminus (N) is located in the cytoplasma, followed by 12 stretches of hydrophobic 
residues arranged in two sets of six successional transmembrane spanning α-helices 
(M1 and M2). The sequence of M1 and M2 is separated by a large hydrophilic loop of 
360 to 390 amino acids (C1) and terminated by a cytoplasmic domain containing 255 
to 330 amino acids (C2) and the carboxyl-terminus (C) (Iyengar, 1993; Sunahara et 
al., 1996). C1 and C2 form the catalytic core (Tang et al., 1995) and can both be 
further divided into “a” and “b” subdomains (Zhang et al., 1997a; 1997b). The 
intracellular regions C1a and C2a are highly conserved and share 50 to 90% of 
sequence homology among the different AC isoforms (Sunahara et al., 1996).  
 
 
 
 
extracellular
intracellular
 
 
Fig. A.2. Schematic illustration of a mammalian membrane-bound AC (Tang and 
Gilman, 1992; Sunahara et al., 1996). The proposed structure is characterized by the 
intracellular N- and C-termini, the two membrane-spanning domains M1 and M2 and 
the cytosolic regions C1 and C2. The formation of the catalytic core by the two 
subdomains C1a  and C2a is responsible for the conversion of ATP into cAMP. 
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Crystallographic and mutational studies revealed the essential role of these 
two domains, forming the critical cleft in AC reaction (Mou et al., 2005). In the 
presence of activators like forskolin or GSα, a conformational change enhances the 
affinity of C1a to C2a (Whisnant et al., 1996; Yan et al., 1996). During catalysis, an 
interface between the two domains is formed by the interaction of polar and charged 
regions (Tang and Gilman, 1992; Zhang et al., 1997a; 1997b). C1b and C2b are less 
conserved, and their role is as yet poorly understood. C1b is assumed to be 
responsible for isoform-specific regulation (Yan et al., 2001; Beeler et al., 2004). The 
predicted functions of the two transmembrane domains are on the one hand a stable 
anchoring at the plasma membrane and on the other hand the coordination of C1/C2 
interaction (Hanoune et al., 1997; Hurley, 1998).  
Binding of ATP induces another conformational change (proof reading), which 
enables the enzyme to bind the substrate (Yoo et al., 2004). Hydrogen bonds 
between the nitrogen (1N)-atom of the adenine base and Lys938 and in addition, 
between the (6N)-atom and Asp1018 (numbering according to AC2) ensure specifity 
for adenine (Liu et al., 1997; Tesmer et al., 1997). For example, due to the high 
similarity of ACs to guanylyl cyclases (GCs), GTP is bound to AC with 10-fold lower 
affinity, but no turnover to cGMP takes place (Sunahara et al., 1998; Tang and 
Hurley, 1998; Beuve, 1999).  
The conversion of ATP into cyclic AMP is initiated by the binding of the 
adenine base into a hydrophobic pocket at the catalytic site (Tang and Hurley, 1998). 
The negatively charged phosphate tail of the nucleotide with its α-, β- and γ-
phosphate interacts with the positive side chains from both sides of the cleft, e.g. 
Arg484, Arg1029 and Lys1065 (numbering from AC2) as well as Arg398 and 
Arg1011 (numbering from AC1) (Tang and Hurley, 1998). The catalysis is induced by 
the inversion of the configuration at the α-phosphate. Subsequently, the 
pyrophosphate is displaced by an intramolecular nucleophilic attack of the 3’-OH 
group of the ATP ribose on the 3’-oxygen atom of the α-phosphate (Eckstein et al., 
1981; Dessauer et al., 1996; Liu et al., 1997; Tang and Hurley, 1998).  
Mutagenesis and kinetic analysis uncovered an essential role for Asn1025 and 
Arg1029 of C2 in catalysis (Yan et al., 1997; Zhang et al., 1997a; 1997b). Both amino 
acids form a water-mediated interaction with the adenine (Yan et al., 1997). Arg1029 
interacts with the α-phosphorus atom (Liu et al., 1997, Tesmer et al., 1997), while 
Asn1025 is close to the 3’-O atom of the current ATP complex and assists Arg1029 
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in stabilizing the transition state or the leaving group. Asp354 in AC1 is identified to 
be the crucial catalytic base (Liu et al., 1997; Tesmer et al., 1997), because 
mutations of this amino acid have disruptive effects on the binding of ATP and lead to 
complete inactivation of AC (Tang et al., 1995).  
For adequate AC activity, Mg2+ or Mn2+ is required in molar excess of ATP 
(Garbers and Johnson, 1975; Somkuti et al., 1982). A single Mg2+ ion binds to a pair 
of aspartates on C1 (Tesmer et al., 1997), a second metal ion binding site is 
contained within the C2 domain (Mitterauer et al., 1998). These divalent cations are 
supposed to participate in catalysis by activating the 3’-OH group and/or stabilizing 
the transition state of the α-phosphate (Mitterauer et al., 1998). Nevertheless, the 
precise molecular mechanism of this catalytic reaction is still unknown, due to the 
lack of crystallographic structures of holo-ACs with substrate or substrate analogs.  
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A.1.3  AC Isoform-Specific Regulatory Mechanisms 
Adenylyl cyclases do not only exist as multiple isoforms with specific molecular 
diversity, they are also characterized by regulatory complexity with distinct signal 
integration (Defer et al., 2000; Kristiansen, 2004).  
 
A.1.3.1 GSα 
The common GPCR signal transduction pathway leads from receptor 
activation via a conformational change in the G protein to the interaction of the GSα 
subunit with AC. This progression characterizes the major mechanism to activate AC 
and subsequently produce cAMP (Tang et al., 1992). Activation through GSα 
represents, with few qualitative and quantitative differences, the only natural feature, 
shared by all AC isoforms (Iyengar, 1993; Sunahara et al., 1996). The dissociation 
from the Gβγ complex allows the α-subunit to directly interact and activate AC at a 
picomolar concentration (Tang and Hurley, 1998). Mutagenic mapping discovered a 
functional association of GSα with both cytoplasmic domains C1 and C2 (Sunahara et 
al., 1997; Tesmer et al., 1997). The GSα binding site at adenylyl cyclase has been 
localized to a small hydrophobic region of C1a and, additionally, to a much larger 
negatively charged and also hydrophobic gap on C2a (Tesmer et al., 1997; Yan et al., 
1997a). Binding of GSα enhances the connection of the two cytoplasmic loops and 
imposes a conformational change on the catalytic core. While the key residues 
converge to the 3’-OH group of ATP, the active site wraps around ATP and catalysis 
proceeds faster (Harry et al., 1997; Sunahara et al., 1997; Tesmer et al., 1997).  
 
A.1.3.2 Giα/Goα 
Agonist occupation of GPCRs can also generate inhibition of ACs mediated 
through a subunit of Giα or Goα (Tang and Gilman, 1991; Kozasa and Gilman, 1995; 
Taussig and Gilman, 1995). By direct interaction with the C1 domain, Giα stabilizes a 
more open and inactive conformation of the catalytic cleft. In contrast to GSα, which 
uniformly activates all AC isoforms, the subsequent actions of Giα are isoenzyme-
specific (Chen and Iyengar, 1993; Taussig et al., 1993a; Rodbell, 1995). For certain 
AC subtypes, such as types 5 and 6, which are predominantly expressed in kidney, 
and type 1 in the brain, Giα acts as a non-competitive inhibitor of GSα stimulation 
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(Taussig et al., 1993a; Dessauer et al., 1998; Defer et al., 2000). This repressive 
effect on ACs can be blocked by pertussis toxin. Pertussis toxin catalyzes the ADP-
ribosylation of Giα/Goα subunits and thus, uncouples them from their membrane-
bound receptors (Defer et al., 2000; Watts and Neve, 2005). In the opposite, enzyme 
activity of the AC isoforms 2 and 8 are not altered by Giα/Goα (Chen and Iyengar, 
1993; Lustig et al., 1993; Taussig et al., 1993a). Characterizing the response of ACs 
to modulation by Giα/Goα-coupled receptors can even lead to the activation, rather 
than inhibition, of adenylyl cyclases depending on the duration of receptor stimulation 
(Gao and Gilman, 1991; Tang et al., 1992). On the one hand, acute and short 
activation of Giα/Goα-coupled receptors inhibits AC and attenuates cyclic AMP 
accumulation, but on the other hand, prolonged stimulation of Giα/Goα-coupled 
receptors typically sensitizes AC to subsequent activation by FS or GSα-coupled 
receptors (Watts and Neve, 2005).  
 
A.1.3.3 Gβγ 
In addition to Gα modulation, the Gβγ complex is a reasonably potent and direct 
effector on ACs, too (Tang and Gilman, 1991; Taussig et al., 1993b; Kristiansen, 
2004). Only low concentrations of βγ can be achieved by activation of GSα whereas 
the stimulation of Giα/Goα yields substantially higher concentrations, reflecting a 
variety of cross-talks between different receptors (Federman et al., 1992; Bygrave 
and Roberts, 1995; Bayewitch et al., 1998a).  For instance, stimulation of Gq-coupled 
receptors can mediate mobilization of intracellular calcium via Gqα and additionally 
increase cAMP accumulation via modulation of AC by βγ (Gilman, 1987). Depending 
on the affected AC isoform, the Gβγ complex displays different effects: direct 
stimulation in presence of GSα was observed in ACs 2, 4 and 7 (Gao and Gilman, 
1991; Tang and Gilman, 1991), direct inhibition was determined at ACs 1, 5, 6 and 8 
(Robishaw et al., 1986; Smigel, 1986; Bayewitch et al., 1998b) and finally no direct 
effect was seen with ACs 3 and 9 (Fig. A.3) (Iyengar, 1993).  
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Fig. A.3. Patterns of regulation of AC activity (Sunahara et al., 1996). Due to their 
relationship to distinct modulators, the AC isoforms can be divided into three 
categories: Ca2+/CaM-stimulated enzymes 1, 3 and 8 (A), Ca2+-insensitive isoforms 
2, 4, 7 and 9 (B) and finally Ca2+-inhibitable ACs 5 and 6 (C). After GPCR activation   
(    /     /    ), the modulation of the AC isoforms can be in a stimulatory (  ) or inhibitory 
(  ) manner according to the distinct regulator. PKA / PKC, protein kinase A / C; PLC, 
phospholipase C; IP3, insitol 1,4,5-trisphosphate; ER, endoplasmatic reticulum.   
A 
B 
C 
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A.1.3.4 Ca2+/CaM 
Calmodulin is an endogenous calcium-sensor protein, which modulates the 
activity of ACs 1, 3 and 8 (Fig. A.3A) (Tang et al., 1991; Choi et al., 1992b; Cali et al., 
1994). ACs 1 and 8 are activated by direct binding of the Ca2+/CaM complex to a 
putative binding site located in the C1b helical region of AC1 (Vorherr et al., 1993) or 
in the C2 region of AC8 (Levin and Reed, 1995). However, the precise mechanism of 
Ca2+/CaM activation is still unknown. All responses of ACs to Ca2+/CaM are highly 
synergistic with GSα or FS (Choi et al., 1992a; Sunahara et al., 1996). Although AC8 
needs a 5 to 10 times higher concentration of Ca2+/CaM than AC1, the required 
concentration of Ca2+ is still in the physiological range (0.1 to 1 µM). In contrast, the 
effects on AC3 depend on supra-normal Ca2+-concentrations (> 1 µM) (Choi et al., 
1992b). In vivo AC3 and AC9 can be inhibited via Ca2+-dependent calmodulin kinase 
II and calcineurin, respectively (Cali et al., 1994; Antoni et al., 1995; Wei et al., 1996).  
 
A.1.3.5 [Ca2+]i 
Besides the Ca2+/CaM-dependent AC family, the two subtypes AC5 and AC6, 
are strikingly inhibited by submicromolar concentrations of free Ca2+ ([Ca2+]i) (Fig. 
A.3C) (Krupinski et al., 1992; Cooper et al., 1998; Guillou et al., 1999). The inhibition 
of AC5 by [Ca2+]i involves the catalytic domains (Hu et al., 2002) and is additive to 
the effect of Giα activation (Defer et al., 2000). It has been shown that both AC 
isoforms are affected by physiologically relevant concentrations of [Ca2+]i. Their 
inhibition is more intensely mediated by the extracellular entry of Ca2+ through L-type 
Ca2+-channels rather than the release from intracellular stores (Yoshimura and 
Cooper, 1992; Cooper et al., 1994; Cooper et al., 1995). The relation to physiological 
relevance and the higher order of AC regulation by [Ca2+]i are still matter of 
investigation.    
In addition, all AC isoforms are inhibited by submillimolar concentrations of 
[Ca2+]i. This non-physiological effect is possibly competitive with Mg
2+, the essential 
cation for AC reaction (Sunahara et al., 1996; Cooper, 2003).  
 
A.1.3.6 PKA and PKC 
In addition to their regulation by G protein subunits and [Ca2+]i, mammalian 
adenylyl cyclases are also subjected to complex regulation by phosphorylation via 
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protein kinase A (PKA) or protein kinase C (PKC). AC5 and AC6 are sensitive for 
phosphorylation by PKA, which disrupts binding of GSα to AC and causes inactivation 
(Iwami et al., 1995). Certain agonists can activate Gq-coupled receptors, leading to 
PKC activation, which in turn modulates ACs in an isoform-specific manner (Levin 
and Reed, 1995). PKC activates several AC isoforms like ACs 1, 2, 3, 5 and 7 by the 
interaction of their C-terminus with specific phosphorylation sites (Fig. A.3). This, in 
turn, increases the cyclase activity (Bol et al., 1997). In contrast, GSα-stimulated AC4 
and AC6 activity is decreased in presence of PKC mediated by the N-terminal region 
(Fig. A.3B,C) (Kawabe et al., 1994; Zimmermann and Taussig, 1996; Lai et al., 
1999).  
 
A.1.3.7 FS 
The diterpene forskolin (FS) is a very lipophilic compound extracted from the 
roots of the Indian plant Coleus forskohlii (Seamon and Daly, 1986; Yan et al., 
1998a). FS has been utilized as a pharmacologic agent in studies relating to the 
biochemistry and regulation of AC and cAMP in diverse systems (Seamon et al., 
1981). FS potently activates all cloned mammalian adenylyl cyclases except type 9 
by interaction with the two homologous cytoplasmic domains (C1 and C2) that form 
the catalytic core (Metzger and Lindner, 1981; Iyengar, 1993; Premont et al., 1996). 
Sequence analysis revealed that one amino acid (Leu912, AC2 labeling) is 
absolutely conserved in the C2 domain among FS-sensitive type 1 to 8, but differs in 
FS-insensitive type 9 enzyme (Yan et al., 1997a). A single change of Tyr1082 to 
leucine of mammalian type 9 enzyme can confer both binding and activation by 
forskolin (Zhang et al., 1997b; Yan et al., 1998).  
Based on chrystallographic studies, Leu912 is located at the interface of the 
C1/C2 complex, where FS directly binds and interacts with AC (Fig. A.4) (Tang and 
Gilman, 1995; Whisnant et al., 1996; Dessauer et al., 1997; Scholich et al., 1997). 
The FS-binding site in the catalytic core is very close to the GSα-binding site. 
Although there is a greater distance to the ATP binding site, forskolin still affects ATP 
binding (Yan et al., 1998). FS enhances the adhesiveness of the two cytoplasmic 
domains and stabilizes the dimer by closing a hydrophobic gap (Zhang et al., 1997b).  
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Fig. A.4. Proposed interactions of forskolin and the catalytic core of AC (Zhang 
et al., 1997b). The dotted lines indicate the hydrogen bonds between the hydroxyl-
groups of FS and the critical amino acids of the catalytic core. Amino acid labelling 
with “A” refers to the C1 domain, “B” stands for the C2 subunit.  
 
 
Interactions between forskolin and adenylyl cyclase are predominantly 
hydrophobic. However, specificity is enhanced by hydrogen bonds between the 1-OH 
and 9-OH groups of FS and C1 and between the 7-acetyl-group and Ser942 (AC2 
labeling) at C2 (Fig. A.4) (Sutkowski et al., 1994; Robbins et al., 1996; Yan et al., 
1998). Based on these interactions, special modifications of the FS structure 
generate a variety of FS analogs, e.g. 1-deoxy-FS, 9-deoxy-FS or 7-deacetyl-FS. 
These FS derivatives can be used to uncover isoform-specific binding modes 
between the diterpenes and ACs and thus, characterize the interplay between 
activators and ACs (Pinto et al., 2008; 2009). Although FS probably does not 
participate in physiological cAMP signaling, its exceptional efficacy makes it essential 
to understand its mode of actions. The striking effect in a natural regulatory system 
suggests that the FS binding pocket might bind an as yet unidentified physiological 
hydrophobic activator (Zhang et al., 1997b). 
 
A.1.3.8 P-Site Inhibitors 
ACs are subject to inhibition by a class of non-competitive adenosine analogs 
known as P-site inhibitors (Desaubry et al., 1996a; 1996b). These inhibitors are 
ribose-modified (deoxy- and 3’-phosphorylated) adenosine analogs which suppress 
catalysis by acting directly on ACs (Dessauer and Gilman, 1997). They potently 
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interfere with the catalytic site of AC when elevated concentrations of the reaction 
product pyrophosphate (PPi) additionally enhance their binding (Dessauer and 
Gilman, 1997; Dessauer et al., 1999).  
 
A.1.3.9 MANT-Nucleotides 
Nucleoside triphosphates substituted with an N-methylanthraniloyl (MANT)-
group at the 2’- or 3’-oxygen of the ribose were serendipitously identified to act as 
potent AC inhibitors (Gille and Seifert, 2003a; 2003b). MANT-inhibitors occupy the 
same position in the catalytic site as P-site inhibitors and substrate analogs. The 
MANT-fluorophore is integrated into a hydrophobic pocket at the interface of C1 and 
C2 and interacts with lipophilic residues like Phe400, Trp1020 and Val1006 (Mou et 
al., 2005). It acts like a barrier, which prevents the catalytic core of AC to change 
from the open to the closed conformation (Mou et al., 2005). Thus, no cAMP 
synthesis can be catalyzed. Fig. A.5 shows the general structure of different MANT-
nucleotides and the hydrolysis stable nucleoside-γS-triphosphates.   
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Fig. A.5. Structure of 2’(3’)-O-(N-methylanthraniloyl)- (MANT)-substituted 
nucleotides. Different purine and pyrimidine bases attached to the ribose serve as 
substrate to the AC binding site. Substitution of the oxygen in the phosphate tail 
stabilizes the nucleotide for degradation. The MANT-group spontaneously isomerizes 
between the 2’- and 3’-OH of the ribose.   
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Substantial differences in interactions between the base and/or different 
substitution patterns at the phosphate tail of the inhibitors and the binding site of ACs 
are reported (Mou et al., 2006). The catalytic core of ACs was found to be spacious 
and flexible, binding both purine and pyrimidine nucleotides but with varying affinities. 
Moreover, the specific order of inhibitory potency determined for special ACs, 
can be used to characterize and discriminate between the different AC isoforms. The 
isoform-specific inhibition patterns can also serve as basis for the development of 
isoform-selective AC inhibitors. Their application as novel therapeutic drugs could 
lead to new therapies of various diseases associated with AC activation. 
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A.1.4 Tissue Distribution and (Patho)Physiological Relevance of AC Isoforms 
In all mammalian tissues, at least one AC isoform can be found, which 
integrates different regulatory pathways through cross-talk with other signal 
transduction systems (Sunahara et al., 1996; Hanoune and Defer, 2001). The 
determination of the precise expression and attribution to special tissues is crucial to 
classify the activation patterns and to clarify the physiological relevance of the 
different members of the AC family. Over the years, biochemical analysis, 
recombinant technologies, the generation of knock-out mice and transgenic animals 
delivered insights into the physiological roles of AC in defined tissues (Tab. A.1) 
(Hanoune and Defer, 2001). 
  
A.1.4.1 Localization, Functions and Pathophysiological Relevance of ACs 
• AC isoform 1 is expressed in neurons (Xia et al., 1993) and abundant in 
certain areas of the brain, such as in hippocampus, neocortex and the granular cells 
of cerebellum (Mons et al., 1993). AC1 knock-out studies discovered the critical role 
of this isoform in synaptic plasticity and long-term potentiation (LTP) (Wu et al., 1995; 
Storm et al., 1998). LTP is the ability of two neurons to communicate with each other 
and provide a long-lasting enhancement in signal transmission (Villacres et al., 
1998). Moreover, AC1-/- mice showed altered transmission of neuropathic pain 
(Vadakkan et al., 2005) and subsequently a changed behaviour. AC1 overexpression 
in mouse forebrain enhanced recognition and neuromodulation (Wang et al., 2004), 
which confirmed its crucial role in learning and memory (Choi et al., 1992a; Villacres 
et al., 1993; Xia and Storm, 1997).  
In 1994, Schnecko et al. discovered the relationship between neural AC 
isoforms and Alzheimer’s disease (Schnecko et al., 1994). Ca2+/CaM sensitive ACs, 
in particular AC1, are significantly reduced in hippocampus and cerebellum from 
patients suffering from Alzheimer’s disease (Yamamoto et al., 1997). The 
neuropathological changes in the brain as well as excessive activation of neuronal 
receptors result in a damage and dying of nerve cells (Wang et al., 2007). Because 
of the connection of AC1 with learning and memory (Wang et al., 2004), modulation 
of AC1 may be a novel approach in neurodegenerative diseases and Alzheimer’s 
disease (Sadana and Dessauer, 2009). For the development of new potential 
disease-modifying treatments, the development biomarkers would be the next step to 
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specify particular states of the disease (Rosenberg and Hillis, 2009).  
 Additionally, AC1 synthesis is strikingly dependent from the circadian rhythm 
pointing to function as a key regulator of melatonin production and release (Defer et 
al., 2000).   
 
Tab. A.1. Tissue-specific expression of AC isoforms, potential roles and 
possible contributions to malfunction of organs (Iyengar, 1993; Sunahara et al., 
1996; Hanoune et al., 1997; Defer et al., 2000; Ludwig and Seuwen, 2002).   
 
AC isoform Tissue distribution 
Predicted functions and association 
with pathophysiological states 
AC1 Brain, neural tissue 
Learning, memory, Alzheimer’s 
disease, melatonin release 
AC2 
Brain, lung, platelets, 
skeletal muscle 
Synaptic plasticity, cell differentiation, 
respiration 
AC3 
Olfactory epithelium, 
genitals, colon, brain 
Sense of smell, sperm function 
AC4 
Widespread 
Kidney, heart, liver, uterus 
Synaptic coordination, oocyte 
maturation, 
AC5 Kidney, heart, brain 
Cardiac contraction, heart failure, 
polycystic kidney disease 
AC6 
Widespread 
Kidney, heart 
Cardiac contraction, heart failure 
AC7 
Brain, cerebellar granula, 
platelets, heart, lung 
Depression, drug dependency 
AC8 Hippocampus, testis, lung 
Neuroendocrine function,  
drug dependency 
AC9 Brain, endocrine tissues 
Long-term potentiation, signaling 
between motoneurons 
 
 
• Together with AC1, Ca2+-insensitive AC type 2 is predominant in a number of 
brain regions (Furuyama et al., 1993) and regulates synaptic plasticity and neuronal 
differentiation (Mons et al., 1993; Matsuoka et al., 1997). Expression of AC2 with its 
stimulation by PKC is found to modulate cell differentiation and results in inhibition of 
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cell cycle progression (Smit et al., 1998). AC2 is also known to be the prevalent 
isoform in lung (Feinstein et al., 1991), pointing to regulatory mechanisms in 
pulmonary artery myocytes (Furuyama et al., 1993; Jourdan et al., 2001). 
Furthermore, strong expression levels of AC2 have been detected in postmitotic 
neuronal cells and in platelets (Premont et al., 1992; Hanoune and Defer, 2001) as 
well as in skeletal muscle and testis (Ludwig and Seuwen, 2002).   
• Coexpression of AC3 with GSα and Golf, an olfactory form of GSα, is exposed in 
olfactory neuroepithelium indicating an involvement of AC3 in sense of smell 
(Bakalyar and Reed, 1990). AC3 knock-out studies confirmed its crucial role in 
olfaction and olfaction related responses (Wong and Storm, 2002). In spite of the 
presence of other AC isoforms in olfactory cilia, behavioural studies with AC3-/- mice 
showed a complete anosmia (Wong et al., 2000). Although AC3 was originally 
thought to be exclusively expressed in olfactory epithelium, up to date, a broad tissue 
distribution is described with high levels in placenta, testis, ovary and colon (Yang et 
al., 1999; Ludwig and Seuwen, 2002). Low levels are reported in brain, heart, adrenal 
medulla, lung and retina (Xia et al., 1992; Abdel-Majid et al., 2002).  
• AC isoform 4 is widely distributed in a variety of tissues with an appropriate 
multiplicity of physiological roles. The ability of AC4 in the hippocampus to detect 
coincident activation of GSα- and Giα-coupled receptors indicates an association in 
synaptic plasticity by coordinating such overlapping synaptic inputs (Baker et al., 
1999). Another prominent pattern of AC4 is the expression in uterus (Suzuki et al., 
1997) and the contribution to oocyte maturation arrest (Guzman et al., 2005) as well 
as the subjection of the AC4 expression level to sex steroids (Asano et al., 2005). 
Other organs with high levels of AC4 occurrence are e.g. liver, heart and kidney (Gao 
and Gilman, 1991). Unfortunately, the distinct physiological role of AC4 in each of 
these tissues is still subject of survey.  
• Ca2+-sensitive ACs 5 and 6 create a subgroup within the mammalian AC family 
(Katsushika et al., 1992). AC6 is a widespread subtype found in all organs, whereas 
AC5 is more restricted to special tissues (Hanoune and Defer, 2001). In the heart, 
particularly in cardiac myocytes, both ACs are the main isoforms. [Ca2+]i mediates the 
regulation of AC5 and probably also of AC6 in cardiac tissue (Hanoune and Defer, 
2001). The physiological relevance of this Ca2+-inhibition is mainly induced by Ca2+-
influx via L-type Ca2+-channels (Yu et al., 1993). 
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Models of heart failure discovered cardioprotective effects of AC6 and cardiac 
regulation of heart rate and contractility responses of both, AC5 and AC6 (Roth et al., 
1999; Tepe et al., 1999). During heart failure, the expression rate of AC6 decreases, 
whereas the level of AC5 keeps constant (Ping et al., 1997). This indicates a different 
subcellular location of ACs 5 and 6. In fact, AC5 is found to be essentially present in 
myocytes, contrary to non-myocytic AC6 (Yu et al., 1995). AC5 knock-out models are 
protected against cardiomyopathy and oxidative stress (Yan et al., 2007). 
Additionally, they show an apparently increased life span. In contrast, overexpression 
of AC5 in heart reveals no cardioprotective effects. AC activity enhances during 
overexpression without impaired heart function and cardioprotective mechanisms 
(Hanoune and Defer, 2001). In the opposite, AC6 overexpression restores normal 
cardiac function. Enhanced AC6 activity improves contractility (Gao et al., 2002) and 
increases survival in cardiac hypertrophy and cardiomyopathy (Roth et al., 2002). 
Accordingly, AC regulation in heart is very complex and it seems that AC5 and AC6 
play opposing roles during pathophysilogical states of heart function.  
The second major tissue with an abundant expression of AC5 and AC6 are the 
kidneys. AC6 is present all along the nephron, in the medulla (Shen et al., 1997), the 
collecting tubule and the thick ascending limb (Chabardés et al., 1996). However, 
AC5 is more restricted to the glomerulus and the cortical part of the kidney (Ludwig 
and Seuwen, 2002). Ca2+ is known to play a crucial role in urine concencentration, 
thus, the capacitative Ca2+-entry and the intracellular Ca2+-release are important 
regulators of the ACs in the kidney as well (Chabardés et al., 1999). An increase in 
extracellular Ca2+-concentration decreases the hormone-dependent cAMP 
accumulation (Chabardés et al., 1996). Moreover, renal urine production can be 
regulated by the antidiuretic hormone vasopressin via V2-receptor mediated cAMP 
production (Takaichi et al., 1986). In parallel, the high responsiveness of renal ACs to 
activation by glucagon strongly indicates a crucial role of ACs in renal homeostasis 
(Ahloulay et al., 1995).  
• Although the structure of AC7 is closely related to AC2, a quite different 
expression pattern is reported throughout the brain (Hellevuo et al., 1995). mRNA of 
AC7 is particularly present in cerebellar granula (Sunahara et al., 1996). Against the 
background, that reduced activity of the cAMP signaling system has been involved in 
the etiology of depressed individuals, AC7 could have a sex-specific implication in 
depression (Hines et al., 2006). Overexpression of AC7 in the CNS modified the 
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acute responsiveness toward ethanol and increased the sensitivity to morphine 
analgesia (Yoshimura et al., 2000; Patel et al., 2001). A quite widely distribution was 
observed with further occurrence of AC7 in heart (Krupinski et al., 1992), lung 
(Ludwig and Seuwen, 2002), platelets and postmitotic neuronal cells (Hanoune and 
Defer, 2001). 
• AC8 is a brain-specific protein (Parma et al., 1991; Krupinski et al., 1992) and 
the only Ca2+/CaM-stimulated isoform expressed in the hippocampus (Matsuoka et 
al., 1992; Cali et al., 1994; Mons and Cooper, 1994). This indicates the importance of 
AC8 in neuroendocrine function (Wong et al., 1999) and drug dependence (Matsuoka 
et al., 1994; Lane-Ladd et al., 1997). In AC8 knock-outs, neurological defects 
illustrate the critical role of CaM-regulated ACs in higher brain function (Sunahara 
and Taussig, 2002). However, neither increased anxiety nor long-term depression 
appear in single knock-out mice of AC8 after treatment with repeated stress tests 
(Schaefer et al., 2000). In contrast, AC1/AC8 double knock-outs fail in both long-term 
memory and long-term potentiation (Wong et al., 1999).  
AC8 appearance was also reported in testis (Defer et al., 1994) and lung 
(Muglia et al., 1999). 
• AC9 belongs to the most abundant isoforms in brain (Antoni et al., 1998a). It is 
present in postsynaptic dendrites of the neocortex and hippocampus and seems to 
be involved in signaling between motoneurons (Antoni et al., 1998b). AC9 is potently 
inhibited by the Ca2+/CaM-activated protein phosphatase calcineurin (Antoni et al., 
1995). Co-localization of calcineurin with AC9 (Paterson et al., 2000) and the 
coincidental presence of CaM-dependent AC1, AC8 and CaM kinase II indicate a 
high relevance for homeostasis of brain function and particularly LTP (Lu et al., 1996; 
Antoni et al., 1998b; Hanoune and Defer, 2001). Depletion of the AC9 analog in 
Caenorhabditis elegans prevents the organ from GSα-induced neurodegeneration and 
cell death (Berger et al., 1998; Korswagen et al., 1998). This indicates the 
relationship of AC9 to signaling and regulation in motoneurons (Defer et al., 2000). 
AC9 is further expressed in several peripheral endocrine tissues like ovaries and 
testis (Hanoune and Defer, 2001). 
   
A.1.4.2 Connection between Polycystic Kidney Disease and Renal ACs 
Polycystic kidney disease (PKD) is a renal disease, inherited in a more 
prevalent autosomal dominant or in a less frequently autosomal recessive manner 
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(Guay-Woodford and Desmond, 2003; Torres et al., 2007). In the autosomal 
dominant form, two genes are identified to be associated with the pathogenesis: 
PKD1 and PKD2. These genes encode for the membranous glycoproteins polycystin 
1 and polycystin 2, respectively. Polycystin 1 is a receptor associated with ciliary 
sensory and cell adhesion. Polycystin 2 regulates the renal tubular and vascular 
development and in its additional function as a cation channel, it controls the flow of 
Ca2+ in the renal plasma membrane (Hughes et al., 1995; Mochizuki et al., 1996). 
Autosomal recessive polycystic kidney 
disease is linked to a single gene disruption 
of PKHD1, encoding for fibrocystin 
(Bergmann et al., 2004). Both forms are 
characterized by overlapping symptoms like 
numerous fluid-filled cysts in the kidneys 
(Fig. A.6), tubular dilatation and defective 
ciliogenesis (Grantham, 1997). Patients 
suffer from renal pain, hypertension and 
frequent urinary tract infections. Blood in the 
urine often indicates renal function 
abnormalities and renal insufficiency. In the 
end-stage, large cysts also affect other 
tissues like liver and pancreas (Torres and Harris, 2006). During the last decade, a 
major role of cAMP levels in the proliferation of renal cyst epithelial cells and the 
promotion of fluid production was discovered (Yamaguchi et al., 2000; Grantham, 
2003). In response to AC agonists, increased levels of cAMP and cAMP analogs, the 
proliferation of epithelial cells in cyst walls is increased. cAMP also enhances fluid 
secretion and thus, leads to an enlargement of renal cysts (Sullivan and Grantham, 
1996). Unfortunately, until now, no treatment was found to slow cyst formation or 
disease progression. Only palliative therapies ease the severity of the symptoms 
(Wuthrich et al., 2009). With AC-dependent cAMP regulation being a key factor in 
PKD, renal AC isoform-specific inhibition provides a target for the pharmacological 
treatment of this disorder.  
 
Fig. A.6. Polycystic kidney. The 
picture was taken from the Institute 
for Molecular and Cellular Anatomy, 
Prof. Dr. R. Witzgall, University of 
Regensburg, Germany; 
(http://www.biologie.uni-
regensburg.de/Anatomie/index.html). 
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A.2 Several Clues and Unanswered Questions 
In summary, the isoform-specific structure of the catalytic core of AC isoforms 
allows many different regulatory mechanisms to operate solitarily or simultaneously. 
It is perfectly suited to their physiological roles to react to multiple signals with their 
distinct effects. Nevertheless, many questions remain unanswered, e.g. first of all, 
why do cells express multiple isoforms of AC? And how are the mechanisms 
regulated to distinguish the stimulatory or inhibitory outcomes? What is the exact role 
of the transmembrane domains? What is the endogenous ligand for the forskolin 
binding site? What exact roles do ACs play in mental disorders, cardiac function or 
regulatory properties in the kidney and what are the distinct mechanisms? Genetic 
knock-out models and further structure analysis will be necessary to define the 
specific physiological and biochemical roles of each AC family member. A further 
clue for investigation would be the identification of the proteins’ role under disease 
conditions. The basis for precise development of isoform-specific and selective 
pharmaceuticals is the detailed characterization of AC isoforms in all tissues. The 
clarification of all physiological and pathophysiological roles will lead to the 
development of new therapeutic approaches. 
 
A.3 Scope and Objectives of this Thesis 
Polycystic kidney disease, heart failure, Alzheimer’s disease and mood 
disorders are only a few of the numerous pathophysiological states caused by 
malfunction of the adenylyl cyclase family. The nine mammalian membranous AC 
isoforms play a crucial role in transmembrane signaling events of the G protein-
coupled receptor (GPCR) cascade and catalyze the formation of the universal 
second messenger cAMP. Since mACs are expressed in a tissue-specific manner, 
isoform-selective and specific modulation by activators like forskolin and analogs or 
inhibitors like MANT-nucleotides may be a promising novel therapeutic strategy.  
 The aim of this thesis is the characterization of the regulation and modulation 
of AC isoforms using a sensitive and robust assay system. It is planned to clarify the 
effects of FS and six FS derivatives on recombinant ACs expressed in Sf9 insect 
cells. In a biochemical assay we will determine the characteristic AC activity of all 
seven diterpenes, rendering their pharmacological profile. Therefore, the structure-
activity relationships for the studied diterpenes will be explored. Additionally we will 
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investigate the precise contribution of the divalent metal ions Mg2+ in comparison to 
Mn2+, serving as cofactors for mACs. By docking ligands to the isoform-specific mAC 
model, we aim at explaining preferences of ligands for both metal ions. With respect 
to potential therapeutic applications, the clarification of AC regulation is essential. 
The precise mechanism of AC regulation by isoform-selective activators in 
combination with the influence of the divalent metal ions will provide the basis for the 
development of novel drugs targeting mACs.  
 Furthermore, this thesis intends to characterize AC activity in the two main 
parts of the kidney. The expression patterns of the different AC isoforms in renal 
cortex and medulla will be investigated using molecular biological approaches. 
Biochemical methods will be used to analyze differences in activation, inhibition and 
regulation of the AC isoforms in rabbit cortex and medulla membranes. GPCR 
agonist-mediated AC activity, analysis of Ca2+-dependent or calmodulin-sensitive 
cAMP formation and the inhibitory profile of eight 2’(3’)-O-(N-methylanthraniloyl) 
(MANT)-nucleoside 5’-([γ-thio])triphosphates will differentiate between the renal AC 
types and identifiy the prevalent cortical and medullary AC isoform. Since PKD is 
characterized by an overproduction of cAMP predominantly in the collecting duct and 
the distal nephrons, potent inhibitors affecting selectively renal AC isoforms could 
constitute a novel approach to treat PKD. 
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B.1 Abstract 
Forskolin (FS) is an invaluable research tool, activating mammalian 
membranous adenylyl cyclase isoforms 1 to 8 (ACs 1-8). ACs play an important role 
in transmembrane signaling events of many tissues and represent an interesting drug 
target. AC isoform-selective FS analogs could serve as potential novel therapeutic 
approach in the treatment of heart failure or Alzheimer’s disease.  
Therefore, we examined the effects of FS and six FS derivatives on 
recombinant ACs 1, 2 and 5. Correlations of the pharmacological parameters of 
these diterpenes between the different AC isoforms showed a distinct isoform-
specific profile. The most intensive differences were found by comparisons between 
the diterpene potencies on AC1 with AC2 and AC5. Correlations illustrated slopes of 
23.4 ± 8.3 and 9.04 ± 3.5, respectively. Additionally, we observed a large influence of 
the divalent metal ions Mg2+ or Mn2+ on the catalytic activity. Potencies and efficacies 
of FS derivatives changed for the same AC isoform, depending on the provided metal 
ion. The most striking effects of Mg2+ and Mn2+ on the diterpene profile were 
observed for AC2. The large inverse agonistic effect of BODIPY-FS on AC2 in 
presence of Mg2+ was considerably reduced in presence of Mn2+. Docking 
experiments and correlations of the efficacies of diterpenes on the purified catalytic 
subunit C1/C2 of AC plus GSα-GTPγS did not reveal cation-dependent effects. Thus, we 
suggest an influence of the structural environment of the catalytic core and the 
transmembrane domains on cation-dependent diterpene effects.  
In conclusion, AC isoforms 1, 2 and 5 exhibited a distinct pharmacological 
diterpene profile. Additionally, these effects are probably modulated by the divalent 
metal ions serving as cofactors for AC. However, the currently available docking 
results are not conclusive to solve the impact of the divalent cations on AC 
regulation.  
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B.2 Introduction 
Magnesium(II)- and manganese(II)-ions are both essential for human life. Mg2+ 
is the fourth-most abundant metal ion in cells (in moles) and the most abundant free 
divalent cation (Guerrera et al., 2009). Over 300 enzymes, e.g. mammalian adenylyl 
cyclases (mACs) require the presence of magnesium ions for their catalytic action. 
ACs are integral plasma proteins, which play a central role in transmembrane 
signaling. Stimulation of G protein-coupled receptors (GPCRs) is translated via G 
protein activation to the AC-mediated conversion of adenosine 5’-triphosphate (ATP) 
to the second messenger cyclic adenosine 3’,5’-monophosphate (cAMP) (Sutherland, 
1972). In mammals, nine membrane-bound AC isoforms (ACs 1-9) are expressed 
with Mg2+ being the physiological cation for AC activity in vivo (Sunahara et al., 1996; 
Hanoune and Defer, 2001). The various AC subtypes exhibit tissue-specific 
expression and play a crucial role e.g. in cardiac contractility and the regulation of 
kidney or brain function (Hanoune et al., 1997; Defer et al., 2000). The structure of 
membranous ACs is characterized by an intracellular N- and C-terminus, two 
membrane-spanning domains and two cytosolic loops C1 and C2 (Tang and Gilman, 
1992; Sunahara et al., 1996). C1 and C2 form the catalytic core (Tang and Gilman, 
1995) and are highly conserved among the different AC isoforms (Sunahara et al., 
1996).  
The catalytic unit of AC also exhibits regulatory sites for divalent cation 
binding, e.g. Mg2+, by which the activation of the enzymes is directly regulated 
(Londos and Preston, 1977; Limbird, 1981). Additionally, Mg2+ interacts with ATP, the 
substrate of ACs, forming the biologically active chelate Mg-ATP and thus, preparing 
the molecule for the nucleophilic attack by ACs (Garbers and Johnson, 1975).  
In biological systems, manganese ions (Mn2+) are readily capable of replacing 
Mg2+ under certain conditions (Friedberg, 1974; Feig, 2000). Being a trace nutrient, 
Mn2+ functions as cofactor for numerous enzymes like transferases, hydrolases and 
oxidoreductases (Crowley et al., 2000). Since Mn2+ is very similar to Mg2+ in terms of 
its chemical properties, manganese is often exerted as divalent cation in in vitro 
studies (Johnson and Sutherland, 1973). Mn2+ can also replace Mg2+ as the 
activating ion for a number of Mg2+-dependent enzymes, e.g. mACs (Johnson and 
Sutherland, 1973; Cech et al., 1980). Additionally, ATP combined with Mn2+ 
effectively forms chelate complexes similar to Mg-ATP and serve as substrate of AC 
reaction (Garbers and Johnson, 1975; Wei et al., 1979). However, differences in 
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catalytic reactivity of AC have been noted depending on whether Mg2+ or Mn2+ was 
served as the metal cofactor (Perkins, 1973; Wald and Popovtzer, 1984).  
Eight of the nine mammalian membranous AC subtypes (AC1-AC8) are 
activated by the diterpene forskolin (FS), a lipophilic substance extracted from the 
roots of the Indian plant Coleus forskohlii (Seamon and Daly, 1986). FS directly 
interacts with AC and robustly stimulates the enzyme activities. Therefore, it is used 
as a pharmacologic agent promoting cAMP production via AC activation (Seamon 
and Daly, 1981). Although the FS binding site is located at the interface of the 
catalytic units of ACs, the physiological counterpart to FS is as yet unidentified. 
However, FS-containing herbal medicines and life-style products are becoming 
increasingly popular. Moreover, in a recent study, a forskolin-like molecule was 
identified in the cyst fluid of patients suffering from polycystic kidney disease (Putnam 
et al., 2007). A great advance in understanding the biochemical differences of the AC 
isoforms is the development of isoform-specific FS analogs (Onda et al., 2001). 
Isoform-specific forskolin analogs would be of great therapeutic interest, e.g. in the 
treatment of addiction or heart failure and as spasmolytic or antithrombotic agents 
(Metzger and Lindner, 1981).  
In recent studies, we characterized the effects of different diterpenes on ACs 
and investigated the interactions of AC with FS analogs in the presence of Mn2+ 
(Pinto et al., 2008; 2009). However, the precise contribution of Mg2+ in comparison to 
Mn2+ to the pharmacological parameters of diterpenes on AC is still unknown. Here, 
we investigated the influence of Mg2+ and Mn2+ on the effects of FS and FS analogs 
on ACs 1, 2 and 5 and C1/C2. By measuring diterpene-dependent cAMP production 
we observed isoform-specific characteristics of potencies and efficacies. Depending 
on the presence of Mg2+ or Mn2+, the diterpene profiles changed for each AC isoform, 
indicating a profound effect of the metal ion on AC activity. By docking ligands to the 
isoform-specific mAC model we aimed at explaining preferences of ligands for both 
metal ions. 
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B.3 Materials and Methods 
B.3.1 Materials  
Baculoviruses encoding ACs 1, 2 and 5 were a gift from Drs. A. G. Gilman (UT 
Southwestern Medical Center, Dallas, TX, USA) and R. K. Sunahara (University of 
Michigan Medical School, Ann Arbor, MI, USA). Spodoptera frugiperda (Sf9) insect 
cells were from the American Type Cell Culture Collection (Rockville, MD). FS was 
purchased from LC Laboratories (Woburn, MA). DMB-FS was from Calbiochem (San 
Diego, CA). BODIPY-FS was from Molecular Probes (Eugene, OR). All other FS 
analogs were from Sigma-Aldrich (St. Louis, MO). Stock solutions of FS and FS 
analogs (10 mM each) were prepared in DMSO and stored at -20°C. Dilutions of FS 
analogs were prepared in such a way that in all AC assays, a final DMSO 
concentration of 3% (v/v) was achieved. [α−32P]ATP (3,000 Ci/mmol) was purchased 
from PerkinElmer (Wellesley, MA). Aluminum oxide (N Super 1) was purchased from 
MP Biomedicals (Eschwege, Germany). Data were analyzed by linear or non-linear 
regression using the Prism 5.01 program (GraphPad, San Diego, CA). 
 
B.3.2 Membrane Preparation 
Sf9 cell membrane preparation was performed as described (Seifert et al., 
1998). For membrane preparation Sf9 cells (3.0 x 106 cells/mL) were infected with 
correspondent baculovirus encoding different mammalian ACs (1:100 dilutions of 
high-titer virus stocks) and cultured for 48 hours. Briefly, cells were harvested and 
cell suspensions were centrifuged for 10 min at 1,000 x rpm at 4°C. Pellets were 
resuspended in 30 mL PBS buffer containing 137 mM NaCl, 2.6 mM KCl, 0.5 mM 
MgCl2, 0.9 mM CaCl2, 1.5 mM KH2PO4, 0.8 mM Na2HPO4, pH 7.4. After a second 
centrifugation step of 10 min at 1,000 x rpm and 4°C, the pellets were suspended in 
15 mL of lysis buffer (10 mM Tris/HCl, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl 
fluoride, 10 µg/mL leupeptine and 10 µg/mL benzamide, pH 7.4). Thereafter, 
homogenization was performed with 20-25 strokes using a Dounce homogenizer. 
The resultant cell fragment suspension was centrifuged for 5 min at 500 x rpm and 
4°C to sediment nuclei. The cell membrane-containing supernatant suspension was 
centrifuged for 20 min at 18,000 x rpm and 4°C. The supernatant fluid was discarded 
and cell pellets were again suspended in 20 mL lysis buffer. After a second high-
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speed centrifugation step, buffer consisting of 75 mM Tris/HCl, 12.5 mM MgCl2, and 
1 mM EDTA, pH 7.4 was added to the membrane pellets. Aliquots of 1 mL of 
membrane suspension were prepared and stored at -80°C. The protein concentration 
for each membrane preparation was determined by the lowry method using the Bio-
Rad DC protein assay kit (Bio-Rad, Hercules, CA) (Lowry et al., 1951).  
 
B.3.3 AC Activity Assay  
AC activity was determined essentially as described in the literature (Gille et 
al., 2004). Just before experiments, Sf9 membranes with recombinant ACs were 
washed by adding assay buffer consisting of 50 mM triethanolamine and 1 mM 
EGTA, pH 7.4 and then centrifuged with 13,000 x g for 10 min at 4°C. Afterwards,  
membranes were resuspended with syringes in the sequence 21 G and 27 G and 
diluted in assay buffer to a protein concentration of 1 µg/µL. For the determination of 
the effects of FS and FS analogs on AC activity, reaction mixtures contained 7 mM 
Mn2+ or Mg2+, 40 µM ATP, 10 µM GTPγS, 100 µM cAMP, 0.4 mg/mL creatine kinase, 
9 mM phosphocreatine, 100 µM IBMX and 0.3 µCi [α−32P]ATP. FS or FS analogs at 
various concentrations (100 nM – 300 µM) in the presence of 3% (v/v) DMSO were 
added to the assay tubes. After a preincubation time of 2 min at 30°C, reactions were 
initiated by the addition of 20 µL of membrane suspension. Reactions were 
conducted for 10 min at 30°C and were terminated by adding 20 mL of 2.2 N HCl. 
Denatured protein was precipitated by a 2 min centrifugation at room temperature 
and 13,500 x g. Sixty µL of the supernatant fluid were transferred onto columns filled 
with 1.4 g neutral alumina. [32P]cAMP was separated from [α−32P]ATP by elution of 
the product with 4 mL of 0.1 M ammonium acetate, pH 7.0. Samples were filled up 
with 10 mL double-distilled water, and [32P]cAMP was determined by liquid 
scintillation counting of Čerenkov radiation.  
 
B.3.4 Docking FS Derivatives to the Isoform-Specific mAC Model 
Five forskolin derivatives were built and energy-minimized by SYBYL program. 
The docking model mAC protein was generated from the crystal structure of 
membrane-bound adenylyl cyclase VC1 and IIC2 in complex with GSα protein subunit 
and 2’,5’-dideoxy-3’-AMP (PDB ID 1CJU), where co-crystallized forskolin was 
extracted and used as a reference ligand (Tesmer et al., 1999). The charge assigned 
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to the model protein residues and ligands were described previously (Suryanarayana 
et al., 2009). Two magnesium or manganese ions were assigned in the cyclase 
active sites. The Goldscore and Chemscore scoring functions were used to rank 
binding poses. The root mean square deviations (RMSD) represent how well the 
docked ligand conformations were optimally aligned with the reference co-crystallized 
forskolin molecule in the model protein structure.  
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B.4 Results 
B.4.1 Overview on the Structures of Forskolin Analogs 
In order to characterize the activity of different AC subtypes, we examined the 
effects of FS and six FS analogs (Fig. B.1). We studied FS derivatives missing the 
OH-group at 1- or 9- position of the diterpene ring structure referred to as 1d(eoxy)- 
or 9d(eoxy)-FS, respectively. The acetyl group at position 7 is also known to be 
critical for AC activation by direct interaction with Ser942 (Fig. B.2) (Tang and Hurley, 
1998; Pinto et al., 2009). Thus, we examined one derivative without the 7-acetyl-
group (7-deacetyl-FS or 7DA-FS) and one where this acetyl-group switched from 7- 
to the 6-position (6-acetyl-7-deacetyl-FS or 6A7DA-FS). Additionally, we used FS 
analogs with bulky substituents like the only relatively water-soluble FS analog 7-
deacetyl-7-[O-(N-methylpiperazino)-γ-butyryl]-FS (DMB-FS) (Laurenza et al., 1987) 
and boron-dipyrro-methene-FS (BODIPY-FS), which can also be used for fluorescent 
studies (Liu et al., 1998; Takahashi et al., 2002).  
 
 
  
Fig. B.1. Structures of FS and FS analogs analyzed in this study.  
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Fig. B.2. Molecular structure of the FS binding site of mAC (Pinto et al., 2009). 
The AC structure with DMB-FS is superimposed on both C1 and C2 domains of the 
AC structure with FS. A, overview of the molecular surface of the diterpene binding 
pocket coordinated by the purified C1 protein of AC5 (VC1/blue) and the C2 protein of 
AC2 (IIC2/pink). FS and DMB-FS are represented in stick models; carbon atoms are 
gray for FS and yellow for DMB-FS, nitrogens blue, and oxygens red. Amino acids of 
VC1 closely related with the 1-OH group of the diterpene are colored magenta for 
Asp505, green for Val506 and orange for Trp507. A water molecule is coordinated 
between the Ser942 (cyan) from IIC2 and two oxygens of the diterpenes. B, detailed 
view of interactions between secondary structure elements of VC1 (lime), IIC2 (pink) 
and the diterpenes FS (cyan) and DMB-FS (yellow), respectively. Side chains of the 
protein are colored gray, nitrogens blue, and oxygens red. The white dashed lines 
depict the hydrogen bonds between amino acid residues Val506 of VC1 and 1-OH of 
FS (green circle).The hydrogen bonds between Ser942 (IIC2) and 7-OH of FS via a 
water molecule are highlighted in the red circle, the interaction between Ser508 (VC1) 
and 11-OH of FS is shown in the blue circle.  
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B.4.2 Effects of FS and FS Analogs on Recombinant ACs  
Forskolin robustly activates AC isoforms 1, 2 and 5 by the direct interaction of 
the diterpene with its special binding site at the enzyme (Metzger and Lindner, 1981; 
Iyengar, 1993). In the AC activity assay, we examined the effects of FS and six FS 
analogs at increasing concentrations (100 nM to 300 µM) on recombinant ACs 1, 2 
and 5. The permanent G protein activator guanosine 5’-[γ-thio]triphosphate as well as 
the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) and an ATP 
regenerating system were always added to the assay system.  
Fig. B.3 shows the characteristic concentration-response curves of the 
diterpenes on ACs 1, 2 and 5 influenced in the presence of either 7 mM Mg2+ or 7 
mM Mn2+. The determination of the enzyme activity could be used to characterize 
each AC isoform by its special rank order of diterpene potencies or efficacies.  
Tab. B.1 summarizes the diterpene effects on the examined ACs under Mg2+ 
conditions. FS and FS analogs activated recombinant AC1 in the presence of Mg2+ in 
the order of potencies  BODIPY-FS > DMB-FS ~ FS > 6A7DA-FS > 7DA-FS > 9d-FS. 
The order of efficacies was 9d-FS ~ DMB-FS ~ 7DA-FS > 6A7DA-FS > BODIPY-FS 
>> 1d-FS (ineffective).  
In contrast, the pharmacological profile of AC2 differed considerably from the 
other ACs. When Mg2+ was the divalent cation, all diterpenes except BODIPY-FS 
showed lower potencies as compared to ACs 1 and 5 yielding the rank order 
BODIPY-FS >> FS ~ DMB-FS > 9d-FS > 7DA-FS. A special effect was found with 
6A7DA-FS at AC2. In particular, the concentration-dependent effect of 6A7DA-FS 
revealed an inhibition of AC activity at low concentrations (EC50_1: 1.8 ± 5.5 µM), 
whereas 6A7DA at high concentrations increased enzyme activity (EC50_2: 61.2 ± 
28.6 µM) (Fig. B.3C). The maximum inhibition of AC2 was determined at a 
concentration of 10 µM 6A7DA-FS yielding ~ -20% related to the maximum 
stimulation of 300 µM FS on AC2. Thereafter, AC activity increased to a level of ~ 
+20% relative AC activity. BODIPY-FS exhibited a very large inhibitory effect of -
115.9 ± 17.5 % relative to the maximum stimulation of 300 µM FS on AC2. The order 
of efficacy was FS > DMB-FS ~ 7DA-FS > 9d-FS > 6A7DA-FS >> 1d-FS (ineffective) 
> BODIPY-FS.  
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Fig. B.3. Effects of FS and FS analogs on ACs 1, 2 and 5. AC activity was 
determined as described in “Materials and Methods” for increasing concentrations of 
different diterpenes (100 nM – 300 µM). Tubes were incubated for 10 min at 30°C. A, 
concentration response curves of various diterpenes on AC1 in presence of Mg2+. B, 
diterpene effects on AC1 in presence of Mn2+. C, concentration response curves of 
different diterpenes on AC2 in presence of Mg2+. D, effects of FS and analogs on 
AC2 under Mn2+ conditions. E, effects of various diterpenes on AC5 in presence of 
Mg2+. F, diterpene effects on AC5 under Mn2+ conditions. Data shown are 
representative results (mean ± SD) of one of 2-5 experiments performed in duplicates 
or triplicates. The efficacy for each analog was determined by dividing the maximal 
stimulation obtained for the analog by the maximum stimulation obtained by 
treatment with 300 µM FS expressed in percent. 
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Tab. B.1. Potencies and efficacies of FS and FS analogs on recombinant ACs 1, 
2 and 5 in the presence of 7 mM Mg2+. 
Mg2+ AC1 AC2 AC5 
Diterpene 
EC50 
[µM] 
Efficacy 
[%] 
EC50 
[µM] 
Efficacy 
[%] 
EC50 
[µM] 
Efficacy 
[%] 
Forskolin 3.3 ± 1.9 100 47.2 ± 8.1 100 4.6 ± 1.5 100 
DMB-FS 2.5 ± 0.8 
101.5 ± 
11.0 
50.5 ± 22.8 93.5 ± 1.7 
26.2 ± 
11.0 
190.4 ± 
42.6 
6A7DA-
FS 
6.2 ± 1.7 
69.9 ± 
9.2 
EC50_1:  
1.8 ± 5.5 
EC50_2: 
61.2 ± 28.6 
22.9 ± 1 
52.1 ± 
16.7 
99.6 ± 
11.3 
7DA-FS 14.1 ± 3.9 
99.2 ± 
8.7 
507 ± 196 
93.6 ± 
21.6 
215 ± 
91.4 
103.3 ± 
11.1 
9d-FS 16.8 ± 3.0 
103.2 ± 
13.9 
242 ± 113 
79.5 ± 
10.9 
84.2 ± 
41.5 
138.1 ± 
27.0 
1d-FS ineffective 
11.1 ± 
4.7 
ineffective 1.7 ± 3.4 ineffective 
11.6 ± 
6.3 
BODIPY-
FS 
0.7 ± 0.3 
20.0 ± 
2.9 
0.5 ± 0.04 
-115.9 ± 
17.5 
18.3 ± 9.7 
13.2 ± 
1.7 
 
AC activities were determined as described in “Materials and Methods”. Reaction 
mixtures contained 7 mM Mg2+, [α−32P]ATP (0.3 µCi/tube), 10 µM GTPγS, 100 µM 
cAMP, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine, 100 µM IBMX and 
diterpenes at concentrations from 100 nM – 300 µM. Data were analyzed by non-
linear regression to determine the EC50-values. The efficacy for each analog was 
determined by dividing the maximal stimulation obtained for the analog by the 
maximum stimulation obtained by treatment with 300 µM FS expressed in percent.  
 
 
 
The Mg2+-dependent rank order of potencies on AC5 was FS > BODIPY-FS > 
DMB-FS > 6A7DA-FS > 9d-FS > 7DA-FS. DMB-FS generated a remarkably high 
enzyme activity of 190.4 ± 42.6 % related to the stimulation of 300 µM FS. The order 
of efficacies on AC5 was DMB-FS >> 9d-FS > 7DA-FS ~ FS ~ 6A7DA-FS > BODIPY-
FS ~ 1d-FS.  
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Tab. B.2. Effects of FS and FS analogs for recombinant ACs 1, 2 and 5 in the 
presence of 7 mM Mn2+. 
Mn2+ AC1 AC2 AC5 
Diterpene 
EC50 
[µM] 
Efficacy 
[%] 
EC50 
[µM] 
Efficacy 
[%] 
EC50 
[µM] 
Efficacy 
[%] 
Forskolin 3.3 ± 1.3 100 38.4 ± 14.9 100 17.8 ± 6.5 100 
DMB-FS 2.8 ± 1.6 
65.4 ± 
8.9 
50.8 ± 31.2 
46.0 ± 
14.5 
10.9 ± 1.0 
81.4 ± 
14.3 
6A7DA-
FS 
3.0 ± 1.0 
110 ± 
2.2 
16.7 ± 7.4 69.6 ± 3.5 13.4 ± 3.4 
69.8 ± 
7.1 
7DA-FS 9.3 ± 1.7 
108.8 ± 
4.6 
65.1 ± 43.0 57.4 ± 3.1 38.2 ± 6.3 
124.2 ± 
12.9 
9d-FS 17.0 ± 3.3 
98.3 ± 
3.7 
127 ± 31.8 29.5 ± 6.2 51.3 ± 2.8 
108.1 ± 
12.9 
1d-FS ineffective 5.5 ± 4.3 ineffective 0 ± 0 ineffective 0.5 ± 0.4 
BODIPY-
FS 
1.1 ± 0.2 
73.1 ± 
10.3 
0.17 ± 0.07 
-22.7 ± 
11.7 
2.7 ± 1.1 
68.5 ± 
9.3 
 
AC activities were determined as described in “Materials and Methods”. Reaction 
mixtures contained 7 mM Mn2+, [α−32P]ATP (0.3 µCi/tube), 10 µM GTPγS, 100 µM 
cAMP, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine, 100 µM IBMX and 
diterpenes at concentrations from 100 nM – 300 µM. Data were analyzed by non-
linear regression to determine the EC50-values. The efficacy for each analog was 
determined by dividing the maximal stimulation obtained for the analog by the 
maximum stimulation obtained by treatment with 300 µM FS expressed in percent.  
 
The replacement of Mg2+ by Mn2+ had a profound influence on the action of FS 
and FS analogs on ACs.  
Tab. B.2 documents the Mn2+ effects on AC activation, revealing changes in 
the pharmacological profiles of the AC isoforms. Although the rank order of potencies 
on AC1 did not change, the order of efficacies changed to 6A7DA-FS ~ 7DA-FS > FS 
~ 9d-FS > BODIPY-FS > DMB-FS >> 1d-FS (ineffective).  
The influence of the cation species is most clearly seen with the effect of 
6A7DA-FS on AC2 (Fig. B.3D). In the presence of Mn2+, only stimulation on AC2 by 
6A7DA-FS without inhibition at low concentrations was determined. Additionally, the 
inhibitory effect of BODIPY-FS was much smaller under Mn2+ conditions as 
compared to the presence of Mg2+ and reached only -22.7 ± 11.7 % related to FS 
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stimulation at 300 µM. AC2 utilizing Mn-ATP as substrate yielded the rank order of 
potencies BODIPY-FS >> 6A7DA-FS > FS > DMB-FS > 7DA-FS > 9d-FS. The order 
of efficacies on AC2 in presence of Mn2+ was FS > 6A7DA-FS > 7DA-FS > DMB-FS 
> 9d-FS > 1d-FS (ineffective) > BODIPY-FS.  
When the effects of FS analogs on AC5 were assayed using Mn2+, the order of 
potencies showed moderate variations compared to Mg2+ conditions: BODIPY-FS > 
DMB-FS ~ 6A7DA-FS > FS > 7DA-FS > 9d-FS. The rank order of efficacies was 
7DA-FS > 9d-FS > FS > DMB-FS > 6A7DA-FS ~ BODIPY-FS >> 1d-FS. 
Interestingly, maximal relative AC stimulation on AC5 is lower for all diterpenes 
except BODIPY-FS in presence of Mn2+ than in presence of Mg2+. However, absolute 
values of AC activity were higher with Mn2+ compared to Mg2+ (data not shown).   
 
B.4.3 Comparison of the Biochemical Profiles of Recombinant AC Isoforms 
For each AC isoform we determined a characteristic diterpene profile, 
distinguishing the different AC subtypes. Linear regression analysis assists to 
illustrate differences in enzyme activities. In the presence of Mg2+, correlations of the 
EC50-values on ACs 1, 2 and 5 with each other identified differences in their 
pharmacological profiles. As shown in Fig. B.4A and B, stimulatory potencies on AC1 
compared to AC2 and AC5 resulted in very steep slopes of 23.4 ± 8.3 and 9.04 ± 3.5, 
respectively. If the pharmacological profiles of two different AC isoforms under 
comparison are identical, a slope of 1.0 should be obtained. Thus, remarkable 
differences in the diterpene profile were obtained presenting lower affinities of FS 
analogs to AC5 as compared to AC1 and very low potencies on AC2 (Fig. B.4A and 
B). The corresponding correlation coefficients (r2) of 0.73 and 0.62 differ considerably 
from unity and various diterpenes show very different deviations from the ideal 
correlation line with a slope of 1.0. Therefore, the profound divergence of the 
obtained correlation lines from the ideal correlation line is a result of both, the unique 
biochemical properties of the different AC isoforms and the specific nature of the 
individual diterpenes. 
The correlation of AC2 and AC5 shown in Fig. B.4C, revealed a slope of 0.41 
± 0.04 with an r2 of 0.97 indicating that FS and the six FS analogs bind only with less 
than half of the affinity to AC2 than to AC5 in presence of Mg2+.  
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Fig. B.4. Correlation of the potencies of FS analogs on the different AC 
isoforms. A, correlation of AC1 vs. AC2 in presence of Mg2+ (r2 = 0.73; slope = 23.4 
± 8.3; p = 0.07). B, correlation of AC1 vs. AC5 under Mg2+ conditions (r2 = 0.62; slope 
= 9.04 ± 3.5; p = 0.06). C, correlation of AC2 with AC5 in presence of Mg2+ (r2 = 0.97; 
slope = 0.41 ± 0.04; p = 0.002). D, correlation of AC1 vs. AC2 under Mn2+ conditions 
(r2 = 0.92; slope = 8.00 ± 1.2; p = 0.003). E, correlation of AC1 with AC5 in the 
presence of Mn2+ (r2 = 0.94; slope = 3.0 ± 0.36; p = 0.001). F, correlation of AC2 and 
AC5 under Mn2+ conditions (r2 = 0.86; slope = 0.34 ± 0.07; p = 0.008). Note the 
different scales of the x- and y-axes in A, B, D and F. Comparisons were analyzed by 
linear regression; the dashed lines indicate 95% confidence intervals. The diagonal 
dotted line has a slope of 1.0 and represents a theoretical curve for identical values. 
 
 
The influence of Mn2+ revealed isoform-specific patterns of EC50-values 
determined for FS and FS analogs. Consistently for all diterpenes (r2 ~ 1), the 
stimulatory potencies on AC1 compared to AC2 and AC5 were considerably higher, 
expressed by slopes of 8.0 ± 1.2 for AC1 vs. AC2 and 3.0 ± 0.36 for AC1 vs. AC5 
(Fig. B.4D-F).  
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Fig. B.5. Correlation of the efficacies of the diterpenes on each recombinant AC 
isoform compared to each other. A, correlation of AC1 vs. AC2 in presence of 
Mg2+ (r2 = 0.75; slope = 1.61 ± 0.5; p = 0.026). B, correlation of AC1 vs. AC5 under 
Mg2+ conditions (r2 = 0.86; slope = 1.49 ± 0.3; p = 0.008). C, correlation of AC2 with 
AC5 in presence of Mg2+ (r2 = 0.59; slope = 0.66 ± 0.28; p = 0.074). D, correlation of 
AC1 vs. AC2 under Mn2+ conditions (r2 = 0.39; slope = 0.80 ± 0.50; p = 0.19). E, 
correlation of AC1 with AC5 in the presence of Mn2+ (r2 = 0.76; slope = 0.94 ± 0.27; p 
= 0.02). F, correlation of AC2 and AC5 under Mn2+ conditions (r2 = 0.38; slope = 0.52 
± 0.33; p = 0.19). Comparisons were analyzed by linear regression; the dashed lines 
indicate 95% confidence intervals. The diagonal dotted line has a slope of 1.0 and 
represents a theoretical curve for identical values. 
 
Focusing on the comparison of the efficacies determined for the diterpenes on 
ACs 1, 2 and 5, no similarity was found under Mg2+ conditions (Fig. B.5A-C). 
Independently from the divalent metal ion, the maximum stimulation of the different 
ACs by FS analogs does not yield a uniform picture (Fig. B.5). Some substances like 
7DA-FS or DMB-FS stimulate ACs 1, 2 or 5 more effectively, whereas other 
compounds, e.g. 6A7DA-FS or BODIPY-FS, yield lower AC activity in some cases, 
reflected by data points outside the 95% confidence interval. Under Mn2+ conditions 
correlations of efficacies of FS analogs on AC1 with AC2 or AC5, respectively, are 
characterized by slopes close to 1.0, but the correlation coefficients are very low (r2 = 
0.39, r2 = 0.76) (Fig. B.5D and E). Thus, no correlation could be detected for the 
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efficacies of the different AC subtypes among each other with Mn2+ used as the 
divalent cation (p > 0.01) (Fig. B.5D-F). 
The correlations shown in Fig. B.4 and B.5 do not only illustrate differences in  
the diterpene profiles of the different AC isoforms, they also point to the high impact 
of the divalent cations on AC reaction. In the presence of either Mg2+ or Mn2+, 
biochemical parameters were clearly modulated yielding considerable variations of 
the regression profiles. In Fig. B.4, a clear influence of the divalent metal ion on the 
potencies of the diterpenes is documented. However, the impact of Mg2+ or Mn2+ on 
the efficacies is smaller than the effects on the potencies of FS analogs (Fig. B.5).  
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Fig. B.6. Correlation of potencies and efficacies of FS and FS analogs under 
Mg2+ conditions vs. under Mn2+ conditions. A-C, correlation of isoform-specific 
EC50-values determined in presence of Mg
2+ vs. in presence of Mn2+. D-F, correlation 
of the efficacies on ACs 1, 2 and 5, respectively, Mg2+ conditions vs. Mn2+ conditions. 
A, r2 = 0.86; slope = 0.80 ± 0.2; p = 0.0028. B, r2 = 0.36; slope = 0.16 ± 0.11; p = 
0.21. C, r2 = 0.49; slope = 0.17 ± 0.08; p = 0.08. D, r2 = 0.41; slope = 0.56 ± 0.18; p = 
0.12. E, r2 = 0.61; slope = 0.51 ± 0.18; p = 0.04. F, r2 = 0.34; slope = 0.37 ± 0.23; p = 
0.17. Data were analyzed by linear regression; the dashed lines indicate 95% 
confidence intervals. The diagonal dotted line has a slope of 1.0 and represents a 
theoretical curve for identical values.  
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To highlight the AC-sensitivity to divalent cations, we compared the 
corresponding pharmacological parameters of each AC isoform determined in use of 
Mg2+ with those in presence of Mn2+ (Fig. B.6). Striking effects on the diterpene 
profile depending on whether Mg2+ or Mn2+ serves the role of cation cofactor are 
confirmed for AC2 and AC5 (Fig. B.6B, C, E and F). The lowest impact of the cations 
was determined for the potencies of AC1 (r2 = 0.86; slope = 0.80 ± 0.2) (Fig. B.6A). 
All other correlations showed clear deviations from theoretical identity with slopes 
and r2 of 1.0.  
In our previous work (Pinto et al., 2009), we determined efficacies of FS and 
analogs on C1/C2 catalytic activity plus GSα-GTPγS either in presence of Mg
2+ or Mn2+ 
(Tab. B.3). Correlating these data, we found that the cation effect is less prominent in 
case of the purified catalytic subunit C1/C2 of AC plus GSα-GTPγS (Fig. B.7). Only 
6A7DA-FS and 9d-FS differ from the theoretical curve for identical values shown as 
the dotted line in Fig. B.7.   
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Fig. B.7. Correlation of efficacies of 
FS and analogs on C1/C2 catalytic 
activity plus GSα-GTPγS. The data of 
Tab. B.3 were analyzed by linear 
regression; the dashed lines indicate 
95% confidence intervals. The 
diagonal dotted line has a slope of 
1.0 and represents a theoretical curve 
for identical values. 
Tab. B.3. Efficacies of diterpenes for 
activation of C1/C2 catalytic activity. Data 
were taken from (Pinto et al., 2009). 
Experiments were conducted in the 
presence of Mg2+ or Mn2+ (10 mM each), 
and in presence of C1 (3 nM), C2 (15 nM) 
plus GSα-GTPγS (50 nM).  
 
 
 
 C1/C2 + GSα 
Diterpene 
Efficacy [%]  
Mg2+ 
Efficacy [%]  
Mn2+ 
Forskolin 100 100 
DMB-FS 33 ± 1 41 ± 6 
6A7DA-FS 43 ± 2 83 ± 14 
7DA-FS 83 ± 2 86 ± 3 
9d-FS 33 ± 17 79 ± 13 
1d-FS ineffective (0) 0.5 ± 0.4 
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B.4.4 Docking Results for mAC to Forskolin Derivatives 
By docking FS and analogs to the mAC protein, we aimed to predict 
preferences of diterpenes for binding to AC in the presence of Mg2+ or Mn2+. 
However, the docking preferences of the ligands were about the same for both metal 
ions. For Mg2+ ions as well as for Mn2+ ions, the resulting order was DMB-FS > 9d-FS 
> FS > 1d-FS > 7DA-FS > 6A7DA-FS (Tab. B.4). Thus, the docking method 
appeared to be insufficiently to reproduce the effects of the divalent cations.  
 
Tab. B.4. Results of docking studies for mAC to FS and FS analogs. 
Mg2+ Mn2+ 
Ligands 
Fitness RMSD Fitness RMSD 
FS 40.32 0.603 39.4 0.574 
DMB-FS 48.50 1.030 50.73 0.997 
1d-FS 30.22 2.649 29.10 2.622 
9d-FS 44.38 2.345 43.80 2.341 
7DA-FS 27.41 2.310 26.62 2.259 
6A7DA-FS 24.69 2.422 25.94 2.540 
 
Five forskolin derivatives were built and energy-minimized by SYBYL program. The 
docking was generated on a model mAC protein, i.e. the crystal structure of 
membrane-bound AC VC1 and IIC2 in complex with GSα protein subunit and 2’,5’-
dideoxy-3’-AMP (PDB ID 1CJU). Co-crystallized forskolin was used as a reference 
ligand. The root mean square deviations (RMSD) represent the goodness of 
alignment compared to the reference ligand in the model protein structure. 
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B.5 Discussion 
B.5.1 Interaction of Diterpenes with mAC Isoforms 
Forskolin is an essential tool for the investigation of AC activity. FS and the 
different FS analogs interact with the catalytic subunit of all mAC isoforms except 
type 9 (Seamon and Daly, 1981; Tang and Gilman, 1995). Yan et al. identified a 
mutation in one single amino acid in the C2 domain of AC9 being responsible for the 
loss of activation by FS (Yan et al., 1997). The change of this amino acid Tyr1082 to 
the highly conserved leucine of FS-sensitive ACs 1 to 8 can confer both binding of FS 
to, and activation of AC9 (Zhang et al., 1997; Yan et al., 1998).  
Due to its diterpene structure, interactions between FS and AC are 
predominantly hydrophobic involving ten aliphatic and aromatic side chains within the 
FS binding pocket (Zhang et al., 1997). The interactions of mACs and FS are highly 
conserved among the FS-sensitive ACs 1 to 8. Crystallographic studies showed a 
crucial role of the hydrogen bonds between the 1-OH group of FS and the backbone 
oxygen of Val506 at the C1 catalytical domain of AC (Fig. B.2) (Sutkowski et al., 
1994; Tesmer et al., 1997). Thus, the missing 1-OH group at 1d-FS yielded an 
antagonizing effect at all AC isoforms due to the loss of the interaction with Val506. 
The 9-OH group of FS resides in a binding region at AC without any hydrogen bonds, 
just set in a close distance to the hydrogen bond of 1-OH (Zhang et al., 1997). This 
only indirect interaction of 9d-FS with AC was reflected by effective stimulation of 
ACs 1 and 5. This indicates that the interactions between the 9-OH group of the 
diterpene and the C1 domain of AC1 or AC5 are of less importance for catalysis. 
However, on AC2 the missing 9-OH group reduces efficacy, particularly in presence 
of Mn2+. This may be due to a further, as yet unidentified hydrogen bond between the 
9-OH group and this AC isoform. The absence of the acetyl-group at position 7 was 
tolerated well by all ACs, as is evident from effective AC stimulation. However, it 
resulted in a decrease in potency compared to FS. These results are consistent with 
the evidence of Zhang et al. that the interaction of the 7-acetyl-group with Ser942 is 
important but not essential for FS activity (Fig. B.2) (Zhang et al., 1997). Additionally, 
the switch of the acetyl-group from position 7 to 6 resulted in effective stimulation of 
ACs 1 and 5. Since the efficacy of 6A7DA-FS on AC2 was smaller, the 6-acetyl-
substitution seems to partially prevent this isoform from catalysis. Surprisingly, the 
bulky FS analog BODIPY-FS, originally introduced as fluorescent probe for 
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localization of ACs in intact cells (Liu et al., 1998; Takahashi et al., 2002), showed 
considerable inverse agonistic effects on AC2 in presence of Mn2+ and to a larger 
extent in the presence of Mg2+. Previously, we described the position of the BODIPY-
group outside the FS binding pocket during interaction with AC (Pinto et al., 2008). 
Probably, there is a distinct environment of the catalytic core at AC2 with several 
amino acids surrounding the BODIPY-substituent differently compared to the other 
ACs. The exceedingly effective AC5 activation by DMB-FS suggests that the DMB-
group exhibits favorable interactions with this isoform.  
Studying the diterpene effects on the purified catalytic subunits C1/C2, most of 
the FS analogs yield similar efficacies, particularly in the presence of Mn2+. 
Compared to the corresponding efficacies on recombinant ACs 1, 2 and 5, the 
efficacies on C1/C2 are lower in all cases, except compared to AC2 with Mn
2+. 
Although the functional groups of the crucial amino acids are similar in all examined 
AC isoforms (Tang and Hurley, 1998), the non-homologous regions of AC seem to 
modify diterpene binding. Mou et al. demonstrated by mutational analysis of two non-
conserved amino acids, that residues outside the catalytic site also influence isoform 
selectivity (Mou et al., 2005). Additionally, an involvement of some sidechains of the 
transmembrane domains in AC catalysis is postulated by binding the nucleotide 
substrate, stabilizing the transition state and neutralizing the negative charge of the 
PPi leaving group (Tesmer and Sprang, 1998). Thus, the structural environment of 
the catalytic core influences the confomational change of the catalytic core 
undergoing from the inactive “open” to the active “closed” domain arrangement. 
In agreement with our previous study, all seven diterpenes affect the 
examined AC isoforms in a characteristic manner (Pinto et al., 2008). Correlations of 
the biochemical parameters illustrate characteristic properties of the different AC 
isoforms, suggesting that not only the highly conserved amino acids essential for FS 
binding have an influence on diterpene affinity (Iyengar, 1993; Tang and Hurley, 
1998). Moreover, the significant differences in the structural environment of the 
catalytic core and the transmembrane domains between the distinct AC isoforms 
modify diterpene binding indirectly (Sunahara et al., 1996; Tang and Hurley, 1998).  
This hypothesis will be further examined in molecular modeling studies based 
on the mAC crystal structure adopted in the inactive open conformation or the 
catalytically active closed structure (Tesmer et al., 1997). FS analogs can be 
modeled in both conformations to illustrate differences in the residues responsible for 
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the arrangement of the diterpenes in the binding pocket. Additionally, crystallographic 
studies should detect conformational changes after binding of diterpenes to the 
catalytic core. Unfortunately, at first issues concerning the solubility of the diterpenes 
and the stability of the protein complex have to be handled successfully.  
 
B.5.2 Comparison of Mg2+ vs. Mn2+ as Divalent Metal Ions 
ACs require the binding of metal ions for catalytic activity (Seamon and Daly, 
1981; Johnson et al., 1989; Dessauer et al., 1997). Tesmer et al. demonstrated the 
binding of two metal ions in a crystal structure of the C1/C2-substrate complex 
(Tesmer et al., 1999). The first metal ion (metal A) is coordinated to the aspartic acid 
residues Asp396 and Asp440 and a water molecule (Tesmer et al., 1999). This ion 
serves as Lewis acid and enhances the intracellular nucleophilic attac on the 3’-OH 
of ATP by the α-phosphate (Zimmermann et al., 1998; Tesmer et al., 2000). The 
second metal ion (metal B) is chelated by Asp396, Asp440 and the carbonyl oxygen 
of Ile397 (Tesmer and Sprang, 1998). In closed conformation of the enzyme, it is 
coordinated to the β- and γ-phosphates of the substrate and stabilizes the transition 
state (Mou et al., 2005).  
Mg2+ or Mn2+ can satisfy this cation requirement and influence the binding of 
activators such as FS and FS analogs (Cech et al., 1980). In this study, we focused 
on the role of metal-enzyme interactions with Mg2+ and Mn2+ ions as divalent cations. 
Comparisons of potencies and efficacies determined with FS and its analogs in 
relation to the divalent metal ion showed significant influence of the metal cofactor on 
enzyme activity. In previous studies with mACs, we already obtained differential 
impacts of Mg2+ and Mn2+ on inhibitors like MANT-nucleotides (Gille and Seifert, 
2003; Gille et al., 2004) or activators like FS and analogs (Göttle et al., 2009; Pinto et 
al., 2009). In most cases, the exchange of Mn2+ against Mg2+ increased potencies 
and efficacies of inhibitors as well as of activators. Additionally, the determination of 
kinetic parameters showed a preference of Mn2+ at AC isoforms, supporting the view 
that the metal ions interact differentially with ACs (Gille et al., 2004; Göttle et al., 
2009). These data indicate that Mn2+ is a much more effective activator than the 
physiological ligand Mg2+ (Mou et al., 2005). Additionally, different AC subtypes yield 
distinct signal recognition using Mg2+ or Mn2+ with effects shown on basal activity as 
well as on FS activated ACs (Pieroni et al., 1995). 
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Analysis of crystal structures and docking experiments obtained only small 
global and local differences between the arrangements of Mg2+ and Mn2+ complexes 
(Gille et al., 2004). Electron density for the B-site metal ion is well defined with Mg2+ 
and Mn2+, but density for A-site is weaker than that for the B-site in the Mg2+-bound 
complex (Mou et al., 2005). Additionally, weak electrostatic interactions are possible 
between the substrate and Mn2+, whereas the smaller Mg2+ is less accessible (Gille 
et al., 2004). Thus, the occupancy of Mg2+ at the A-site appears to be lower than that 
of Mn2+ and the active site of the enzyme adopts a slightly more open conformation 
with Mg2+ than in presence of Mn2+ (Mou et al., 2005; Mou et al., 2009).  
However, the metal cofactors showed no impact on the efficacies of FS and 
analogs of the isolated C1/C2 catalytic subunit plus GSα-GTPγS  (Pinto et al., 2009). 
Moreover, in this study, we focused on the structural basis by docking FS and 
analogs to the C1/C2 mAC protein, but no metal ion-dependent change in the docking 
preferences was observed. Since all amino acids involved in FS binding are present 
at all FS-sensitive AC isoforms (Tang and Hurley, 1998), the currently available 
docking methods are not sensitive enough to identify the long-distance 
conformational changes between the catalytic and the regulatory site of cation 
binding. Moreover, the resolution of the data by molecular modeling is insufficient to 
allow accurate measurement of metal coordination bond lengths. 
Although there are substantial differences in the activity of AC isoforms, due to 
differential regulation by metal ions, the biological significance of Mn2+ in the 
regulation of substrate binding and catalyzing cAMP production remains unclear 
(Mitterauer et al., 1998; Zimmermann et al., 1998; Tesmer et al., 1999). mACs 
acquire two metal ion binding sites coordinated to the catalytic core, where Mn2+ 
preferentially binds to the binding site B (Mitterauer et al., 1998; Tesmer and Sprang, 
1998). Although it cannot be excluded that Mn2+ serves as cofactor for catalysis in 
vivo, it is more likely that Mg2+ is the relevant divalent cation under physiological 
conditions (Sunahara and Taussig, 2002).  
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C.1 Abstract 
Polycycstic kidney disease (PKD) is the most common life-threatening genetic 
disorder without an adequate therapy against disease progression. PKD is 
characterized by numerous bilateral renal cysts caused by an increased level of 
cyclic adenosine 3’,5’-monophosphate (cAMP). With adenylyl cyclases (ACs) 
catalyzing the synthesis of cAMP, the pharmacological characterization of the renal 
AC isoforms is essential.  
Therefore, we analyzed differences in activation, inhibition and regulation of 
the AC isoforms in rabbit cortex and medulla membranes. Glucagon, [8-
arginine]vasopressin and catecholamines significantly activated cortical AC, however, 
GPCR agonist-dependent cAMP accumulation in medulla was only observed by 
glucagon and AVP. Under Mg2+ conditions the profile of cortical membrane AC 
regarding enzyme kinetics and the inhibitory profile of eight 2’(3’)-O-(N-
methylanthraniloyl) (MANT)-nucleoside 5’-([γ-thio])triphosphates resembled 
recombinant AC5. In contrast, the Ki-values of MANT-nucleotides for medullary 
membrane AC in the presence of the physiological cation Mg2+ and its kinetic 
properties were similar to those determined for recombinant AC1. PCR confirmed 
these correlations detecting mRNA of AC1 and AC5 in medulla and cortex, 
respectively. Cortical AC was sensitive to inhibition by Ca2+, confirming the 
importance of AC5. However, Ca2+/CaM-dependency specific for AC1 was not found 
in medulla.  
In conclusion, according to expression, kinetics and inhibition by MANT-
nucleotides both parts of the kidney differ in their AC isoform activation. Whereas 
Ca2+-inhibitable AC5 was confirmed in renal cortex, the assumed AC1 activation in 
medulla was rejected, pointing to the involvement of another AC isoform with some 
similarity to AC1. Since PKD is characterized by predominant involvement of the 
collecting duct and the distal nephrons located in renal cortex, AC5 might be the 
major AC isoform in this part where cAMP increases cyst growth. Thus, potent and 
selective AC5 inhibitors could constitute a novel approach to treat PKD. 
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C.2 Introduction 
Polycystic kidney disease (PKD) is a genetic renal cystic disorder, inherited in 
an autosomal dominant or recessive form (Sweeney and Avner, 2006; Torres et al., 
2007). PKD pathogenesis is associated with numerous fluid-filled cysts in the 
kidneys, malfunction of primary cilia and hematuria (Harris and Torres, 2006). 
Frequent urinary tract infections and nephrolithiasis weaken the kidney function to the 
end-stage of renal insufficiency (Grantham, 1997). Unfortunately, only palliative 
therapies help to ease the symptoms. However, up to now, no effective treatments 
are known to slow cyst formation in PKD. In the last years, cyclic adenosine 3’,5’-
monophosphate (cAMP) has been unmasked to play a major role in renal cyst growth 
(Grantham, 2003; Yamaguchi et al., 2003). cAMP mediates the increased fluid 
production and secretion as well as the proliferation of epithelial cells in cyst walls 
(Hanaoka and Guggino, 2000). An overproduction of cAMP was detected in 
polycystic tissues, caused by an enhanced activity of renal adenylyl cyclases (ACs) 
(Torres, 2004a; Wang et al., 2010). A changed regulation of AC activity in the kidney 
leads to alterations in the second messenger pathway and thus, causes an 
imbalance of signal transduction of diverse growth factors and physiological stimuli 
(Cheng and Grande, 2007).  
All nine membrane-bound AC isoforms (AC1-AC9) have unique tissue 
distribution patterns. Gene expression studies showed the presence of ACs 4, 5 and 
6 mRNA along the nephron (Defer et al., 2000). More precisely, AC6 has been 
shown to be expressed along the entire nephron (Chabardés et al., 1996) but ACs 4 
and 5 were differently distributed in specific segments of the kidney (Bek et al., 
2001). However, little is known about the renal distribution of individual AC isoforms 
on the protein level. A crucial problem in the field is the lack of availability of AC 
isoform-specific and sensitive antibodies (Defer et al., 2000; Ortíz-Capisano et al., 
2007; Göttle et al., 2009). Moreover, it is still an open question whether a correlation 
exists between the existence of a specific AC protein and regulatory properties.  
Mammalian ACs can be classified into three groups demonstrating significant 
diversity in their regulation in presence of free Ca2+ (Patel et al., 2001). Group one is 
characterized as Ca2+/calmodulin-sensitive and consists of AC types 1, 3 and 8 
(Sunahara et al., 1996; Patel et al., 2001). Binding of calmodulin (CaM), a Ca2+-
dependent protein, enhances their enzyme activity in the presence or absence of the 
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direct AC activator forskolin (FS) (Cooper, 2003). In contrast, enzyme activities of 
types 5 and 6 ACs are effectively inhibited by low concentrations of free Ca2+. The 
last group of AC isoforms contains the types 2, 4, 7 and 9. These isoforms are 
stimulated by Gβγ subunits and are insensitive to Ca
2+-modulation in physiological 
concentrations. The various AC isoforms also differ from each other with respect to 
their activation (and inhibition) pattern by diterpenes (Pinto et al., 2008). Moreover, 
AC isoforms exhibit differential sensitivity to competitive inhibition by MANT-
nucleotides (Gille et al., 2004; Göttle et al., 2009). Furthermore, various AC isoforms 
differ from each other in their kinetic properties. 
The identification of the prevalent AC isoform on protein level in renal cortex 
and medulla would be a further step to a better understanding of kidney function. The 
modulation of one specific AC isoform in cortex or medulla could lead towards a new 
therapy for PKD. cAMP-mediated cell proliferation and fluid secretion in PKD (Wang 
et al., 2010) could be reduced by isoform-dependent inhibition of AC.  
In a recent study, we have characterized mouse heart AC by studying 
expression pattern at the mRNA level and biochemical characterization with respect 
to kinetics, regulation by diterpenes and inhibition by MANT-nucleotides (Göttle et al., 
2009). We compared the properties of heart AC with those of recombinant AC 
isoforms expressed in Sf9 cells and found that the major AC isoform in heart is AC5. 
Using a similar approach, in the present study, we characterized AC in rabbit kindney 
cortex and medulla. Here, we report their identification by biochemical and 
pharmacological analysis. It is far from clear, whether one prevalent AC isoform can 
be identified to be predominantly activated by the variety of modulators. By analysis 
of GPCR agonist-mediated, Ca2+-dependent or calmodulin-sensitive cAMP formation 
we differentiated between the AC types in the two parts of the kidney.  
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C.3 Materials and Methods 
C.3.1 Materials 
Baculoviruses encoding ACs 1, 2 and 5 were kindly provided by Drs. A. G. 
Gilman (UT Southwestern Medical Center, Dallas, TX, USA) and R. K. Sunahara 
(University of Michigan Medical School, Ann Arbor, MI, USA). Sf9 insect cells were 
from the American Type Cell Culture Collection (Rockville, MD, USA). MANT-ITP, 
MANT-CTP and MANT-UTP were synthesized as previously described (Taha et al., 
2009). MANT-ATP, MANT-GTP, MANT-ATPγS, MANT-GTPγS and MANT-ITPγS 
were from Jena Bioscience (Jena, Germany). [α−32P]ATP (3,000 Ci/mmol) was 
purchased from PerkinElmer (Wellesley, MA). Aluminum oxide (N Super 1) was 
purchased from MP Biomedicals (Eschwege, Germany). Glucagon and AVP were 
purchased from American Peptide Company (Sunnyvale, CA).  Histamine, serotonin, 
dopamine, (-)-epinephrine, (-)-norepinephrine, (-)-isoproterenol, cAMP, 
phosphocreatine, IBMX and triethanolamine were from Sigma-Aldrich (St. Louis, 
MO). FS was from LC Laboratories (Woburn, MA). GTP, GTPγS, ATP and creatine 
kinase were purchased from Roche (Mannheim, Germany). CaCl2 dihydrate, MnCl2 
tetrahydrate and MgCl2 hexahydrate (highest quality) were from Merck (Darmstadt, 
Germany). Lyophilized calmodulin from bovine brain was purchased from EMD 
Biosciences (Calbiochem, Darmstadt, Germany).  
 
C.3.2 Semi-Quantitative PCR 
Total RNA was extracted from renal cortex and medulla using 1 mL TRIzol 
reagent (Peqlab, Erlangen, Germany) per 100 mg tissue. Total RNA was reverse-
transcribed into cDNA according to standard protocols by Invitrogen (Gibco BRL). In 
brief, cDNA was synthesized in a 22 µL reaction per sample with 2 µg total RNA, 0.5 
µg/µL oligo(dT)12-18, 0.5 µL 20 U RNAsin (Promega, Madison, WI), 4 µL of 5 x RT-
buffer, 5 µL of 2.5 mM dNTPs, and 20 U Moloney murine leukemia virus RT enzyme 
(GIBCO Life Technologies). Semi-quantitative PCR was performed with the 
TPersonal Thermocycler System from Biometra (Göttingen, Germany), all primer 
sequences were adopted from (Younes et al., 2008) and shown in Tab. C.1. Each 
reaction contained 1 µL cDNA, MgCl2 of 3 mM final concentration in case of AC1, 
otherwise 2.5 mM, 2.5 mM dNTP, 5 µL 10 x RT-buffer, 1 pmol of each primer and 
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0.25 µL 5 U A-Taq polymerase (Promega, Madison, WI). The PCR reaction was 
initiated with a 2-min hot start at 95°C followed by denaturation at 95°C for 30 sec. 
Annealing was perfomed at 66°C for AC1 and 56°C for detection of ACs 4, 5 and 6 
for 30 sec, and extension took place at 72°C for 30 sec. The last 3 steps were 
repeated in 35 cycles for all three AC isoforms and the PCR reaction was terminated 
with a final 5-min extension period at 72°C followed by cooling at 4°C. In parallel 
experiments, each PCR reaction was performed without renal RNA for negative 
control to test for DNA contamination. Finally, the PCR products were separated on a 
2% (m/v) agarose gel and stained with ethidium bromide.   
 
Tab. C.1. Primer sequences for reverse-transcription PCR of AC isoforms in 
rabbit cortex and medulla.  
AC isoform Primer sequence 
AC1 Forward: 5´-TGGCAGCTGCTGCTGGTCAC-3´ 
 Reverse: 5´-CCACCGCGAGCCCGAAGC-3´ 
AC4 Forward: 5´-ATCAGGAAACTTCGGGTAGC-3´ 
 Reverse: 5´-ATATGGTTGGCCAATGTGAC-3´ 
AC5 Forward: 5´-CATGTTCATGTGCAACTCCA-3´ 
 Reverse: 5´-ATGGATCACGCTGATGTTGT-3´ 
AC6 Forward: 5´-GCTGCGGAGAATCACTGTC-3´ 
 Reverse: 5´-TACCCCCATCTCCACACAG-3´ 
 
 
C.3.3 Sf9 Cell Culture and Expression of Recombinant ACs 
Sf9 cells were cultured and infected with 1:100 dilutions of high-titer virus 
stocks as described previously (Houston et al., 2002). Sf9 membranes were prepared 
according to standard protocols (Seifert et al., 1998) and stored at -80°C until use. 
Protein concentrations were determined using the Lowry method (Lowry et al., 1951). 
For the AC activity assay, Sf9 membranes were thawed, washed and sedimented by 
a 10-min centrifugation at 4°C and 13,000 x g to remove residual endogenous 
nucleotides as much as possible. After that they were resuspended in assay buffer as 
described below. 
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C.3.4 Preparation of Renal Cortical and Medullary Membranes 
Whole kidneys were removed from 8 months old male chinchilla bastard 
rabbits, which were housed in cages in a temperature- and light-controlled 
environment according to the German animal protection law. The animals were 
sacrificed by Narcoren i.v. 2 mL/kg body weight. After removal of both kidneys, the 
tissues were immediately separated into cortical and medullary parts, shock-frozen in 
liquid nitrogen as soon as possible and stored at -80°C until use. The next day, rabbit 
kidneys were prepared to membranes according to a previously described protocol 
(Göttle et al., 2009). All membrane preparation and centrifugation steps were 
performed at 4°C. In brief, still frozen parts of cortex or medulla were cut into small 
pieces and transferred into ice-cold homogenization buffer containing 5 mM Tris·HCl, 
pH 7.4, and 5 mM EDTA. Homogenization was performed in a buffer volume 
amounting to 20-fold the tissue weight using a glass-glass homogenizer (Braun, 
Melsungen, Germany) at 1,500 rpm, applying 5 series of 5 strokes each with a 1-min 
cooling period between each series. Organ debris was removed by an 8-min 
centrifugation at 500 x g. The supernatant suspension was sedimented by a 30-min 
centrifugation at 40,000 x g. Membranes were washed in a buffer volume amounting 
to 60-fold of renal tissue weight and sedimented by a 30-min centrifugation at 40,000 
x g. In order to remove residual endogenous ligands and nucleotides, this washing 
procedure was performed three times before the membranes were resuspended in 
assay buffer consisting of 50 mM triethanolamine and 1 mM EGTA, pH 7.4. After 
resuspension with syringes in the sequence 21 G and 27 G, membranes were shock-
frozen in liquid nitrogen and stored at -80°C. Protein concentration was determined 
using Bradford method (Bradford, 1976) with the DC protein assay kit (Bio-Rad, 
Hercules, CA). 
 
C.3.5 AC Activity Assay 
AC activity was determined essentially as described in literature (Göttle et al., 
2009). Just before use, renal membranes were resuspended with syringes and 
diluted with assay buffer to a concentration of 1 µg/µL. AC inhibition was measured 
using 20 µL of reaction mixture consisting of (final) 7 mM Mn2+ or Mg2+, 40 µM ATP, 
10 µM GTP, 10 µM GTPγS, 100 µM cAMP, 0.4 mg/mL creatine kinase, 9 mM 
phosphocreatine, 100 µM IBMX, 100 µM FS and 0.3 µCi [α−32P]ATP. This mixture 
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was added to 10 µL of MANT-nucleotide and preincubated for 2 min at 30°C. 
Reactions were initiated by the addition of 20 µL of membrane suspension. To avoid 
nucleotide degradation, incubation time was reduced to 1-2 min. For activation 
experiments described subsequently, Sf9 membranes expressing recombinant ACs 
were washed and centrifuged with 13,000 x g for 10 min at 4°C before use. 
Afterwards, the protein pellet was resuspended in assay buffer resulting in a 
concentration of 1 µg/µL. In case of cortical or medullary membranes, the protein was 
resuspended to a concentration of 1 µg/µL without previous centrifugation. In order to 
confirm comparability, the AC activity assay was performed under same conditions 
and with same reaction mixtures for recombinant and renal membranes. We ensured 
linear reaction progress for AC activation by incubating tubes for 10 min at 30°C. For 
identification of Km- and Vmax-values, the reaction mixture was added to 10 µL 
ATP/Mn2+ or ATP/Mg2+ in increasing concentrations (1 µM to 1 mM). Experiments 
aiming to detect an influence of CaM on AC activity contained FS dilution (300 nM to 
300 µM) combined with CaM (2 µM) or double-distilled water and 20 µL reaction 
mixture without GTP and FS. For the examination of Ca2+-influence, all AC 
membranes were maximally activated with 300 µM FS. In these experiments, 
reaction mixtures contained varying CaCl2 concentrations from 100 nM to 1 mM. Free 
Ca2+-concentrations were calculated with the WebMax C standard 
(http://www.stanford.edu/~cpatton/maxc.html). For stimulation of ACs via GPCR 
activation GTPγS and FS were omitted from reaction mixtures. All reactions were 
terminated by the addition of 20 µL of 2.2 N HCl, and denatured protein was 
sedimented by a 2-min centrifugation at 13,500 x g. [32P]cAMP was separated from 
[α−
32P]ATP by transferring the samples onto columns containing 1.4 g of neutral 
alumina. [32P]cAMP was eluted by adding 4 mL of 0.1 M ammonium acetate, pH 7.0. 
Blank values were ~0.02% of the total amount of [α−32P]ATP added; substrate 
turnover was < 3% of the total added [α−32P]ATP. Samples were filled up with 10 mL 
ddH2O and Čerenkov radiation was determined. 
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C.3.6 Data Analysis 
Data shown in Tabs. C.1 and C.2 and in Figs. C.2, C.3 and C.8 were obtained 
by non-linear regression analysis, correlations were obtained by linear regression 
analysis performed with the Prism 5.01 software (Graphpad, San Diego, CA). 
Statistical comparisons were performed using the Student’s t-test. Differences were 
considered as statistically significant with p < 0.05 (*), p < 0.01 (**) and p < 0.001 
(***).  
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C.4 Results 
C.4.1 Detection of AC Isoforms in Rabbit Renal Membranes of Cortex and 
Medulla by Semi-Quantitative PCR 
In order to assess the expression of AC isoforms at the mRNA levels in rabbit 
kidney, reverse-transcription polymerase chain reaction (RT-PCR) analysis was 
performed. After mRNA extraction, cDNA synthesis and PCR, cortical and medullary 
samples of same amounts were transferred to 2% (m/v) agarose gels. The AC4 
fragment showed the expected length of 143 base paires (bp), the fragment for AC5 
of 70 bp and the fragment for AC6 of 114 bp in renal cortex and medulla, respectively 
(Fig. C.1). In direct comparison the darker band of AC4 indicated a higher AC4 
mRNA content in the medullary part of the kidney than in the cortex. In contrast, the 
concentration of AC5 mRNA seemed to be higher in renal cortex. AC6 mRNA was 
detected in both cortex and medulla at the same intensity, indicating that this AC 
isoform is expressed along the entire nephron. Additionally, AC1 (84 bp) was 
detected at a low level in both parts of the kidney.  
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Fig. C.1. Detection of AC isoforms in different kidney segments by reverse-
transcription PCR. mRNA was prepared from isolated cortex and medulla, and 
analyzed with primers specific for ACs 1, 4, 5 and 6. Potential contamination was 
checked by excluding the RNA (-). Expected sizes of the PCR products were 84 bp 
for AC1, 143 bp for AC4, 70 bp for AC5 and 114 bp for AC6. 
 
C.4.2 Stimulation of Rabbit Renal ACs with GPCR Agonists 
Membranous ACs are activated via the GPCR – G protein cascade 
(Chabardés et al., 1975; Sunahara and Taussig, 2002). In the AC activity assay we 
examined the effects of various neurotransmitters and hormones on cortical and 
medullary membranes. In the presence of 7 mM Mg2+, glucagon was the most 
efficient GPCR agonist with an over 3-fold increase of AC activity in both cortex and 
medulla. Among all other tested GPCR agonists, significant activation of medullary 
AC was only obtained with AVP (10 µM) (Fig. C.2B). In contrast, in the cortical part, 
more GPCRs mediating AC stimulation were detected. The order of efficacy of the 
tested GPCR agonists was glucagon (40 µM) > vasopressin (10 µM) > epinephrine 
(100 µM) > isoproterenol (100 µM) ~ norepinephrine (100 µM) (Fig. C.2A). The most 
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potent receptor ligands for AC stimulation in cortical membranes were AVP (EC50: 14 
± 7 nM) and isoproterenol (EC50: 22 ± 0.8 nM) followed by glucagon (EC50: 162 ± 64 
nM), epinephrine (EC50: 383 ± 171 nM) and norepinephrine (EC50: 1,250  ± 67 nM).  
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Fig. C.2. Effects of various GPCR agonists on rabbit renal membranes. AC 
activity was determined as described in “Materials and Methods”. Reaction mixtures 
contained 7 mM Mg2+ and were carried out for 10 min at 30°C. A, Concentration 
response curves were determined for renal cortex. B, AC activity in renal medulla 
was measured for histamine, 5-HT, dopamine, (-)-epinephrine, (-)-norepinephrine 
and (-)-isoproterenol (100 µM each), glucagon (40 µM), AVP (10 µM) and GTPγS 
(110 µM) and (2100 µM). Data shown are representative results (mean ± SD) of one 
of at least 3 experiments performed in triplicates. (* p < 0.05; ** p < 0.01; *** p < 
0.001). 
 
 
C.4.3 Enzyme Kinetics of Cortical and Medullary ACs 
Substrate saturation experiments were performed using membranes of both 
parts of the rabbit kidney to determine the Km- and Vmax-values. Under Mn
2+ 
conditions, saturation was already reached at much lower substrate concentrations 
than with Mg2+. In the presence of 7 mM Mg2+, the Km-value of cortical AC was 86 ± 
7.6 µM, consistent with the Km-value determined for recombinant AC5 and closely 
related to cardiac AC (Fig. C.3A, Tab. C.2). The investigation of medullary 
membranes exhibited a Km-value similar to AC1 (Fig. C.3C). Moreover, experiments 
with 7 mM Mn2+ yielded Km-values for cortical and medullary AC in the lower µM 
range, similar to heart AC and recombinant AC5 (Fig. C.3B and D, Tab. C.2).  
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Tab. C.2. Kinetic properties of renal cortical and medullary ACs in comparison 
with heart AC and recombinant ACs 1, 2 and 5 in presence of Mg2+ and Mn2+. 
Parameter 
Mg2+ 
Cortical 
AC 
Medullary 
AC 
Cardiac 
AC 
AC1 AC2 AC5 
Km [µM] 86 ± 7.6 130 ± 1.8 68 ± 5
## 160 ± 20# 110 ± 30# 87 ± 31## 
Vmax 
[pmol·mg
-1
·min
-1
] 
727 ± 
116 
616 ± 81 
1,600 ± 
160## 
660 ± 90# 300 ± 70# 
2,400 ± 
760## 
Mn2+       
Km [µM] 13 ± 2.6 27 ± 3.5 11 ± 2
## 110 ± 29# 99 ± 22# 40 ± 5## 
Vmax 
[pmol·mg
-1
·min
-1
] 
994 ± 
286 
616 ± 121 
1,010 ± 
370## 
1,500 ± 
230# 
1,200 ± 
140# 
1,300 ± 
400## 
 
Saturation experiments were performed as described in “Materials and Methods” with 
increasing ATP/cation concentrations (1-1000 µM under Mg2+ conditions / 1-150 µM 
under Mn2+ conditions). Km- and Vmax-values were obtained by non-linear regression 
analysis and represent the means ± SD of 2-3 independent experiments performed in 
duplicates or triplicates. Values labeled with (#) were taken from (Gille et al., 2004), 
those labeled with (##) were taken from (Göttle et al., 2009).  
 
Chapter 3: Pharmacological Characterization of Rabbit Kidney ACs 
 
77
0 250 500 750 1000
0
500
1000
c(ATP/Mg
2+
) [µM]
A
C
 a
c
ti
v
it
y
[p
m
o
l 
c
A
M
P
/(
m
g
*m
in
)]
0 25 50 75 100
0
500
1000
c(ATP/Mn
2+
) [µM]
0 250 500 750 1000
0
200
400
600
800
c(ATP/Mg
2+
) [µM]
A
C
 a
c
ti
v
it
y
[p
m
o
l 
c
A
M
P
/(
m
g
*m
in
)]
0 25 50 75 100 125 150
0
200
400
600
800
c(ATP/Mn
2+
) [µM]
A
DC
B
 
 
Fig. C.3. Saturation experiments for determination of Km and Vmax on rabbit 
renal cortex and medulla. Reaction mixtures contained 7 mM Mn2+ or Mg2+, 
[α−
32P]ATP (0.3 µCi/tube), 10 µM GTP, 10 µM GTPγS, 100 µM cAMP, 0.4 mg/mL 
creatine kinase, 9 mM phosphocreatine, 100 µM IBMX and 100 µM FS. ATP/Mn2+ or 
ATP/Mg2+ (1 µM to 150 µM and 1 µM to 1 mM, respectively) plus 7 mM of free Mn2+ 
or Mg2+ were added to reaction mixtures. In order to ensure linear reaction progress, 
tubes were incubated for 10 min at 30°C. A, substrate saturation curve for renal 
cortex in the presence of Mg2+. B, substrate saturation curve for cortical membrane 
AC in the presence of Mn2+. C, substrate saturation curve for renal medulla in the 
presence of Mg2+. D, substrate saturation curve for medullary membrane AC in the 
presence of Mn2+. Data shown are representative results (mean ± SD) of one of 2-3 
experiments performed in triplicates. Substrate saturation curves were plotted by 
non-linear regression curve fit of Michaelis-Menten enzyme saturation. 
 
C.4.4 Inhibition of Renal ACs by MANT-Nucleotides in Comparison with ACs 1, 
2 and 5 
Inhibition data were obtained in the AC activity assay following maximum 
stimulation of renal ACs with forskolin and the G protein activator guanosine 5’-[γ-
thio]triphosphate. 2’(3’)-O-(N-Methylanthraniloyl) (MANT)-ITP displayed the highest 
potency on both cortical and medullary AC in presence of Mn2+ as well as in 
presence of Mg2+  with Ki-values in the lower nM range.  
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Tab. C.3. Inhibitory potencies of MANT-nucleotides on rabbit kidney ACs in 
presence of Mg2+ and Mn2+.  
 Cortex Ki [nM] Medulla Ki [nM] 
Nucleotide Mg2+ Mn2+ Mg2+ Mn2+ 
MANT-ATP 1,628 ± 381 61 ± 7 3,558 ± 1930 125 ± 48 
MANT-ATPγS 706 ± 114 60 ± 10 872 ± 53 75 ± 6 
MANT-CTP 4,141 ± 47 51 ± 9 3,115 ± 290 72 ± 6 
MANT-GTP 1,087 ± 364 13 ± 4 1,285 ± 3 32 ± 2 
MANT-GTPγS 666 ± 120 27 ± 0.3 450 ± 86 42 ± 15 
MANT-ITP 30 ± 6 6 ± 2 29 ± 1 9 ± 4 
MANT-ITPγS 47 ± 9 10 ± 3 48 ± 12 14 ±7  
MANT-UTP 1,500 ± 148 22 ± 3 1,468 ± 192 31 ± 4 
 
Inhibition constants (Ki) on renal ACs were determined as described in “Materials and 
Methods”. To avoid nucleotide degradation, incubation time was reduced to 1-2 min. 
Inhibition curves were analyzed by non-linear regression. Ki-values were calculated 
by Cheng-Prusoff equation and represent the means ± SD of 2-4 independent 
experiments performed in duplicates. 
 
In the presence of Mg2+, the rank order of potency of inhibitors for cortical AC 
was MANT-ITP > MANT-ITPγS >> MANT-GTPγS > MANT-ATPγS > MANT-GTP > 
MANT-UTP > MANT-ATP >> MANT-CTP (Tab. C.3). Under the same conditions, the 
order of inhibitory potency at mouse heart AC was MANT-ITP ~ MANT-ITPγS > 
MANT-GTPγS > MANT-ATPγS ~ MANT-GTP > MANT-UTP > MANT-ATP > MANT-
CTP (Göttle et al., 2009). Recombinant AC5 yielded the following order of potencies: 
MANT-ITP > MANT-ITPγS > MANT-GTPγS > MANT-GTP > MANT-UTP ~ MANT-
ATPγS > MANT-ATP > MANT-CTP (Göttle et al., 2009). The characteristic sequence 
of the inhibitory affinities on AC1 looked quite similar with MANT-ITP > MANT-ITPγS 
> MANT-GTPγS > MANT-ATPγS ~ MANT-GTP > MANT-UTP > MANT-ATP > MANT-
CTP and was closely related to the sequence of inhibitors’ potency on AC2: MANT-
ITP > MANT-ITPγS > MANT-GTPγS > MANT-ATPγS > MANT-GTP > MANT-ATP > 
MANT-UTP > MANT-CTP (Göttle et al., 2009). Comparing all these sequences by 
linear regression, a significant correlation between cortical AC and AC5 as well as 
between cortical AC and cardiac AC was found, p ≤ 0.0001, respectively (Fig. C.4). 
However, linear regression analysis of inhibitor affinities on AC1 revealed a less 
significant correlation with renal cortical AC (r2 = 0.8; slope = 0.86 ± 0.2; p = 0.003). 
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The correlation of the order of Ki-values on AC2 with cortical AC was even less 
significant with a slope of 3.7 ± 0.5.  
0 1 2 3 4 5
0
1
2
3
4
5
MANT-ATP
MANT-ATPyS
MANT-CTP
MANT-GTP
MANT-GTPyS
MANT-ITP
MANT-ITPyS
MANT-UTP
Ki on cortical AC [µM] Mg
2+
K
i 
o
n
 A
C
1
 [
µ
M
] 
M
g
2
+
0 5 10 15 20
0
5
10
15
20
MANT-ATP
MANT-ATPyS
MANT-CTP
MANT-GTP
MANT-GTPyS
MANT-ITP
MANT-ITPyS
MANT-UTP
Ki on cortical AC [µM] Mg
2+
K
i 
o
n
 A
C
2
 [
µ
M
] 
M
g
2
+
0 1 2 3 4 5
0
1
2
3
4
5
MANT-ATP
MANT-ATPyS
MANT-CTP
MANT-GTP
MANT-GTPyS
MANT-ITP
MANT-ITPyS
MANT-UTP
Ki on cortical AC [µM] Mg
2+
K
i 
o
n
 A
C
5
 [
µ
M
] 
M
g
2
+
0 1 2 3 4 5
0
1
2
3
4
5
MANT-ATP
MANT-ATPyS
MANT-CTP
MANT-GTP
MANT-GTPyS
MANT-ITP
MANT-ITPyS
MANT-UTP
Ki on cortical AC [µM] Mg
2+
K
i 
o
n
 h
e
a
rt
 A
C
 [
µ
M
] 
M
g
2
+
A
DC
B
 
 
Fig. C.4. Correlations of cortical Ki-values with the profiles of recombinant and 
cortical ACs under Mg2+ conditions. Data shown in Tab. C.3 were correlated with 
the inhibition constants of MANT-nucleotides on recombinant AC1, AC2 and AC5, 
respectively, and on mouse heart membranes. These values were taken from (Göttle 
et al., 2009). A, correlation of cortical AC vs. AC1 (r2 = 0.80; slope = 0.86 ± 0.2; p = 
0.003). B, correlation of cortical AC vs. AC2 (r2 = 0.90; slope = 3.7 ± 0.5; p = 0.0004). 
C, correlation of cortical AC vs. AC5 (r2 = 0.93; slope = 0.86 ± 0.1; p = 0.0001). D, 
correlation of cortical AC vs. cardiac AC (r2 = 0.94; slope = 0.8 ± 0.08; p < 0.0001). 
Data were analysed by linear regression; the dashed lines indicate the 95% 
confidence intervals of the regression lines. The diagonal dotted line has a slope of 
1.0 and represents a theoretical curve for identical values.   
 
 
Inhibition constants obtained under Mn2+ conditions were generally lower, from 
3- to 5-fold for MANT-ITP and MANT-ITPγS up to almost 45- to 70-fold for MANT-
UTP. The rank order of inhibition potency on cortical AC was MANT-ITP > MANT-
ITPγS > MANT-GTP > MANT-UTP > MANT-GTPγS > MANT-CTP > MANT-ATPγS ~ 
MANT-ATP (Tab. C.3). Compared to the rank order of recombinant AC1 only MANT-
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GTP changed its position: MANT-ITP > MANT-ITPγS > MANT-UTP > MANT-GTPγS 
> MANT-GTP > MANT-CTP > MANT-ATPγS > MANT-ATP. Cardiac AC revealed a 
more considerably altered inhibition sequence of MANT-ITP > MANT-ITPγS > MANT-
UTP > MANT-GTP ~ MANT-GTPγS > MANT-CTP > MANT-ATP > MANT-ATPγS. 
However, the rank orders of inhibition on AC2 (MANT-ITP > MANT-ITPγS > MANT-
GTPγS ~ MANT-ATPγS > MANT-UTP > MANT-GTP > MANT-CTP > MANT-ATP) 
and AC5 (MANT-ITP > MANT-ITPγS > MANT-UTP > MANT-GTPγS > MANT-GTP > 
MANT-ATPγS > MANT-CTP > MANT-ATP) showed only little similarity compared to 
cortical AC. Additionally, no significant correlation with AC1, 2 and 5, was found, and 
the slope was >> 2. However, the comparison of the inhibition profile obtained for 
cortical membranes and cardiac AC yielded the best fit (r2 = 0.83; slope = 0.98 ± 
0.18; p = 0.0014) (Fig. C.5), suggesting similar AC isoform composition in cortex and 
heart.  
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Fig. C.5. Correlations of cortical Ki-values with the profiles of recombinant ACs 
and cortical AC in the presence of Mn2+. Data shown in Tab. C.3 were correlated 
with the inhibition constants of MANT-nucleotides on Sf9 membranes expressing 
AC1, AC2 and AC5, respectively, and on mouse heart membranes adopted from 
(Göttle et al., 2009). A, correlation of cortical AC vs. AC1 (r2 = 0.86; slope = 2.9 ± 0.5; 
p = 0.0008). B, correlation of cortical AC vs. AC2 (r2 = 0.44; slope = 8.2 ± 3.8; p = 
0.0725). C, correlation of cortical AC vs. AC5 (r2 = 0.70; slope = 2.5 ± 0.7; p = 
0.0110). D, correlation of cortical AC vs. cardiac AC (r2 = 0.83; slope = 0.98 ± 0.18; p 
= 0.0014). Comparisons were analyzed by linear regression; the dashed lines 
indicate 95% confidence intervals. The diagonal dotted line has a slope of 1.0 and 
represents a theoretical curve for identical values.   
 
 
The rank order of Ki-values for medullary AC in presence of Mg
2+ was MANT-
ITP > MANT-ITPγS >> MANT-GTPγS > MANT-ATPγS > MANT-GTP ~ MANT-UTP > 
MANT-CTP ~ MANT-ATP (Tab. C.3). The Ki-values for medullary AC correlated well 
with those for AC1 (r2 = 0.95; slope = 0.92 ± 0.1; p < 0.0001) (Fig. C.6) while 
correlations with AC5 as well as with mouse heart AC showed moderate differences, 
r2 < 0.85, respectively. The inhibitor profile of AC2 was again completely different, r2 
= 0.56; slope = 2.9 ± 1.1; p = 0.0332.  
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The medullary inhibition profile in presence of Mn2+ resulted in the potency 
rank order MANT-ITP > MANT-ITPγS > MANT-UTP ~ MANT-GTP > MANT-GTPγS > 
MANT-CTP > MANT-ATPγS > MANT-ATP (Tab. C.3). Compared to ACs 1, 2, 5 and 
mouse heart AC (Fig. C.7), no significant correlation was observed with medullary 
AC, indicating that under these conditions another AC isoform than AC1, 2, 5 or 
cardiac AC was unmasked. 
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Fig. C.6. Correlations of medullary Ki-values with the order of inhibition 
constants of MANT-nucleotides on AC1, AC2, AC5 and cortical AC under Mg2+ 
conditions. Results shown in Tab. C.3 were compared with the Ki-values of 
recombinant AC1, AC2 and AC5, respectively, and on mouse heart membranes. 
These data were taken from (Göttle et al., 2009). A, correlation of cortical AC vs. AC1 
(r2 = 0.95; slope = 0.92 ± 0.1; p < 0.0001). B, correlation of cortical AC vs. AC2 (r2 = 
0.56; slope = 2.9 ± 1.1; p = 0.0332). C, correlation of cortical AC vs. AC5 (r2 = 0.77; 
slope = 0.78 ± 0.17; p = 0.0041). D, correlation of cortical AC vs. cardiac AC (r2 = 
0.84; slope = 0.77 ± 0.14; p = 0.0014). Comparisons were analyzed by linear 
regression; the dashed lines indicate the 95% confidence intervals of the regression 
lines. The diagonal dotted line has a slope of 1.0 and represents a theoretical curve 
for identical values.   
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Fig. C.7. Correlations of medullary Ki-values with the order of inhibition 
constants of MANT-nucleotides on recombinbant and cortical AC in presence 
of Mn2+. Results shown in Tab. C.3 were compared with the Ki-values of recombinant 
AC1, AC2 and AC5, respectively, and on mouse heart membranes (Göttle et al., 
2009). A, r2 = 0.92; slope = 1.76 ± 0.2; p = 0.0002. B, r2 = 0.63; slope = 5.8 ± 1.8; p = 
0.0179.  C, r2 = 0.87; slope = 1.64 ± 0.26; p = 0.0007. D, r2 = 0.80; slope = 0.56 ± 0.1; 
p = 0.0027. Data were analyzed by linear regression; the dashed lines indicate the 
95% confidence intervals of the regression lines. The diagonal dotted line has a 
slope of 1.0 and represents a theoretical curve for identical values.   
 
 
Correlation of the cortical inhibiton profile vs. medullary Ki-values (Fig. C.8) 
identified moderate differences in presence of Mg2+ (r2 = 0.65; slope = 0.82 ± 0.24; p 
= 0.0008) whereas in presence of Mn2+ the differences between the two parts of the 
kidney were more considerable with a slope of 1.6 ± 0.26 pointing to different AC 
isoform expression patterns.  
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Fig. C.8. Correlation of cortical inhibition profile vs. medullary Ki-values. Data 
shown in Tab. C.3 were analyzed by linear regression. A, correlation of cortical AC 
with medullary AC in presence of Mg2+ (r2 = 0.65; slope = 0.82 ± 0.24; p = 0.0008). B, 
correlation of cortical AC with medullary AC in presence of Mn2+ (r2 = 0.86; slope = 
1.6 ± 0.26; p = 0.0155). Comparisons were analyzed by linear regression; the dashed 
lines indicate the 95% confidence intervals of the regression lines. The diagonal 
dotted line has a slope of 1.0 and represents a theoretical curve for identical values.   
 
 
C.4.5 Analysis of Ca2+/CaM-Dependency of AC 1 and Medullary AC 
Detection of AC1 mRNA by PCR, the lack of curve fit of the inhibition profiles 
between medullary AC and cortical AC and cardiac AC, respectively (Fig. C.8) and 
the good correlation with AC1 under Mg2+ conditions (Fig. C.6) suggested that AC 
isoform 1 could play an important role in renal medulla. To further assess the 
potential involvement of AC1 in renal medulla, we studied the effect of calmodulin to 
discriminate Ca2+/CaM-dependent AC1 from other AC isoforms. CaM increased 
basal activity of recombinant AC1 by ~ 4-fold (Fig. C.9A). In contrast, medullary AC 
showed identical responses to FS activation in presence and absence of CaM (Fig. 
C.9B) indicating the presence of another AC isoform than AC1 but characterized by 
similar inhibition properties.  
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Fig. C.9. Activation of recombinant AC1 and renal medullary AC by FS in 
presence and absence of calmodulin (CaM). Both experiments were performed in 
presence of 7 mM Mg2+ and enzyme activity was determined as described in 
“Materials and Methods”. A, Concentration response curves of recombinant AC1. B, 
Determination of AC activation on medullary AC. The data points are presented as 
the mean activities ± SD of duplicate determinations from representative experiments 
performed three times on two separate membrane preparations. 
 
 
C.4.6 Ca2+-Dependent Regulation of Recombinant and Renal AC Isoforms 
Ca2+ added to the reaction mixture differentially influenced enzyme activity 
(Fig. C.10). AC2 showed a linear inhibition pattern. The inhibition profiles of AC5 and 
cortical AC were biphasic illustrating physiologically relevant AC inhibition with Ca2+-
concentrations in the submicromolar range (EC50_1: 300 nM) and by non-
physiological submillimolar Ca2+-concentrations (EC50_2: 200 µM). Both ACs showed 
a similar sensitivity to increasing Ca2+-concentrations. In contrast, ACs 1 and 
medullary AC were rather insensitive to inhibition by Ca2+. Only high concentrations 
of free Ca2+ decreased cAMP synthesis. 
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Fig. C.10. Differential inhibition of various ACs by Ca2+. Reaction mixtures 
contained 7 mM Mg2+, [α−32P]ATP (0.3 µCi/tube), 10 µM GTP, 10 µM GTPγS, 100 
µM cAMP, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine, 100 µM IBMX, 300 
µM FS and Ca2+ in increasing concentrations from 100 nM to 1 mM. To ensure linear 
reaction progress, tubes were incubated for 10 min at 30°C. A, inhibition of AC 
activity by Ca2+ on recombinant AC1. B, Ca2+-dependent inhibition of AC2. C, effects 
of increasing Ca2+-concentrations on AC5. D, inhibition of AC activity by Ca2+ on 
cortical membranes. E, Ca2+-dependent inhibition of medullary AC. Data shown are 
the combinations of 3 independent experiments, presented as the mean activities ± 
SD. Statistical significance was tested using the Student’s t-test (* p < 0.05; ** p < 
0.01; *** p < 0.001). 
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C.5 Discussion 
There is much evidence that overproduction of cAMP plays an essential role in 
cyst growth and the pathogenesis of polycystic kidney disease (Schwiebert et al., 
2002; Wallace et al., 2002). With ACs catalyzing cAMP synthesis, we focused on the 
identification of the predominant AC isoforms in the kidney cortex and medulla.  
 
C.5.1 Semi-Quantitative PCR 
First, we analyzed the expression of ACs in the kidney on mRNA levels. RT-
PCR studies demonstrated the presence of ACs 4, 5 and 6 in rabbit cortex and 
medulla. Ca2+-inhibitable isoform 6 was determined at similar concentrations in both 
parts of the tissue, according to literature, where AC6 expression has been 
demonstrated along the entire nephron (Chabardés et al., 1996). Compared to 
medulla, we found AC5 occurring in higher amounts in the cortex corresponding to 
the data of Heliés-Toussaint et al. (Heliés-Toussaint et al., 2000). Type 4 mRNA 
seemed to be more abundant in the medullary part. Bek et. al. initially discussed a 
more widely distribution of AC4 in the kidney than previously thought (Bek et al., 
2001). This assumption confirms our results that AC4 mRNA is not only restricted to 
the glomerulus (Chabardés et al., 1996; Ludwig and Seuwen, 2002). Additionally, we 
demonstrated mRNA presence of AC1 in rabbit kidney. In literature, this isoform is 
discussed to be neurospecific (Xia et al., 1993) and expressed in special areas of the 
brain (Xia and Storm, 1997). However, since kidney is densely innervated (Barajas et 
al., 1992), the detection of AC1 may reflect the presence of this isoform in neurons. It 
is also possible that AC1 is present in cortical or medullary parenchymal tissue 
(Tiniakos et al., 2004).  
For further investigation, AC expression should have been analyzed at the 
protein level. Unfortunately, there is a paucity of selective and sensitive AC isoform 
antibodies (Defer et al., 2000; Ortíz-Capisano et al., 2007). To this end, all of our 
substantial efforts in this area have been without success both with respect to 
detection of recombinant ACs and ACs in native tissues (data not shown) (Göttle et 
al., 2009). Considering these substantial limitations, we took a biochemical approach 
to characterize AC in cortical and medullary membranes in comparison to selected 
recombinant AC isoforms.  
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C.5.2 Effects of GPCR Agonists on Renal ACs 
Various hormones and neurotransmitters such as glucagon, AVP, epinephrine 
and norepinephrine regulate tubular functions by activation of G protein-coupled 
receptors (Störk and Schmitt, 2002). AVP effectively activates AC in renal cortex and 
medulla. Gattone et al. demonstrated the up-regulation of AVP in PKD and its 
function as modulator of cystogenesis (Gattone et al., 2003; Belibi and Edelstein, 
2010). Consequently, the development of V2-receptor antagonists may reduce renal 
cAMP and inhibit disease progression (Torres, 2004; Wang et al., 2005).  
Moreover, the renin-angiotensin system is involved in functional and structural 
changes during PKD (Belibi and Edelstein, 2010). With glucagon influencing the 
regulation of renin release (Schweda et al., 2007), it appears to be a second peptide 
modulating cyst formation. Glucagon increased AC ~3-fold in cortex and medulla. 
Appropriately, it excites the most effective responsiveness of all activators. Glucagon 
is also known to modulate water and salt homeostasis, glomerular filtration rate and 
renal blood flow (Ahloulay et al., 1995; Marks et al., 2003).  
In contrast, we observed biological responses to catecholamines with 
restriction to the cortical part. α- and β-Adrenergic receptors are expressed along the 
renal tubule (Cohen and Katz, 1991; Meister et al., 1994; Mandon et al., 1995) and 
mediate the physiological effects like stimulation of renin synthesis and antidiuresis 
(Beck et al., 1972). Up to now, there is no evidence for an involvement of 
catecholamines to the pathogenesis of PKD.   
 
C.5.3 Comparison of Renal AC to Recombinant and Cardiac AC  
The determination of the kinetic properties for cortex and medulla showed 
modest differences compared to recombinant ACs. However, the Km-values are 
necessary to calculate the associated inhibition constants of the MANT-nucleotides. 
The inhibition of cortical and medullary ACs by eight different MANT-nucleotides 
yielded a characteristic rank order of potencies for each part of the kidney. In 
presence of Mg2+, the physiological cation involved in AC enzyme activity, there was 
a poor correlation of cortical AC with AC2. Consequently, it is rather unlikely that AC2 
is of major importance in renal cortical tissue. A closer correlation was obtained for 
cortical AC and AC1, however, recombinant AC5 showed the best correlation. 
Another hint for AC5 being the prevalent isoenzyme in renal cortex is the high 
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similarity of cortical AC with cardiac AC. Recently, we confirmed the consistency of 
cardiac AC with AC5 (Göttle et al., 2009). The correlation of the inhibitor profile in 
cortex and heart points to the predominance of AC5 in both systems.  
Under Mn2+ conditions, no correlation of inhibitor profiles was found for cortical 
AC and recombinant ACs. Only cardiac AC showed high similarity. Previously, we 
noticed the varying influences of the different divalent cations on the inhibitor profile 
(Göttle et al., 2009). Under physiological conditions, cortical as well as cardiac AC 
activity resembled AC5 activation. Under non-physiological Mn2+ conditions, another 
AC isoform seemed to be unmasked.  
To verify AC5 as major cortical AC, the different sensitivity of specific ACs to 
Ca2+ was studied. AC subtypes are classified into three distinct families, (i) Ca2+-
stimulated ACs 1, 3 and 8, (ii) Ca2+-inhibited AC5 and AC6 and (iii) unresponsive to 
Ca2+ (ACs 2, 4 and 7) (Cooper et al., 1994a; Cooper et al., 1995; Sunahara et al., 
1996). Independently of this classification, Ca2+ at supramicromolar concentrations 
reduces cAMP formation by all AC isoforms (Cooper et al., 1994a; Guillou et al., 
1999). This inhibition by non-physiological Ca2+-concentrations is not isoform-specific 
and a competition between Ca2+ and Mg2+, the physiological cation needed for AC 
activation (Hu et al., 2002). Physiologically relevant AC inhibition with Ca2+-
concentrations in the submicromolar range has only been described for ACs 5 and 6 
(Guillou et al., 1999). Their Ca2+-dependent inhibition yields biphasic curves based 
on the combination of the physiological and the non-physiological inhibitory effects 
(Hu et al., 2002; Mou et al., 2009).  
In the present study, we compared the inhibition patterns of Ca2+ on 
recombinant ACs 1, 2 and 5 and both renal parts to differentiate between the AC 
subclasses. Although AC2 is known to be insensitive for physiological Ca2+-inhibition 
(Cooper et al., 1995), we showed a linear reduction of cAMP accumulation due to 
increasing Ca2+-concentrations. However, no renal AC resembled the AC2 
characteristic. In contrast, the Ca2+-influence on AC5 membrane was biphasic (Hu et 
al., 2002). With rabbit cortical membranes we detected an analogous biphasic 
inhibition, compatible with AC5.  
Contrary to cortical AC, the examination of medullary AC inhibition by MANT-
nucleotides revealed low similarity with AC5 under both Mg2+ and Mn2+ conditions. 
The obtained rank orders showed clear variations from a theoretical identitiy with a 
slope of 1.0. Direct comparison of cortical and medullary AC inhibition also revealed 
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moderate differences in presence of Mg2+, whereas Mn2+ emphasized the 
discrepancies between the two renal parts. Additionally, the inhibitor profiles of renal 
medulla and mouse heart showed divergent correlations indicating the predominance 
of another AC isoform in medulla than AC5.  
Surprisingly, in presence of Mg2+, inhibition data of renal medulla resembled 
the one of Ca2+/CaM sensitive AC1. This unexpected similarity and the detection of 
AC1 mRNA in medulla suggested the presence of AC1 also on protein level. 
Moreover, focusing on the Ca2+-dependence, medullary AC revealed a Ca2+-sensitive 
profile similar to AC1. Membranes expressing recombinant AC1 only exhibited the 
inhibition effect with high concentrations of Ca2+ and in the absence of CaM (Cooper 
et al., 1994). At low Ca2+-concentrations, stimulation of AC1 only appears in 
presence of calmodulin (Guillou et al., 1999).   
To confirm the AC1 hypothesis, we performed studies with CaM on medullary 
and recombinant Sf9 cell membranes. Ca2+ and CaM activate AC1 by interacting with 
the first cytoplasmatic loop (Cooper et al., 1995; Ferguson and Storm, 2004; Masada 
et al., 2009). CaM also increased sensitivity of AC1 to FS and yielded an additive 
effect (Tang et al., 1991). This effect was confirmed for the recombinant Sf9 
membrane. In contrast, this additive activation was missing at medulla. Although, 
under Mg2+ conditions the prevalent isoform in medulla represented characteristics 
similar to AC1, with respect to the lack of Ca2+/CaM sensitivity, this isoform could be 
excluded. Therefore, another AC different from type 1 was stimulated. 
The intention of our study was the biochemical characterization of renal ACs in 
rabbit kidney. Our data suggest that AC5 is the prevalent isoform in cortex. Although, 
in case of medulla, we could not identify a major AC isoform, we excluded the 
predominance of ACs 1, 2 and 5. Therefore another isoform, different from type 1, 
but with similar pharmacological characteristics seemed to play a crucial role in the 
medulla. Our findings and the confirmation of AC5 in renal cortex are an important 
step to the development of isoform-selective AC inhibitors and a prospective 
therapeutic strategy for PKD. In future studies, further AC isoforms should be tested 
to get detailed information about isoform-specific AC regulation. Unfortunately, the 
stable and active expression of the remaining AC isoforms has to be solved first. 
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D.1 Summary 
Mammalian adenylyl cyclases (mACs) are integral membrane proteins 
involved in various physiological processes. For instance, they regulate cardiac 
contractility and kidney function. Malfunctions or the abnormal regulation of AC 
isoforms cause numerous disease states such like heart failure, polycystic kidney 
disease (PKD), neurodegenerative diseases, or pain and drug dependency. During 
the past decades, nine distinct mammalian membranous AC isoforms have been 
identified. These exhibit isoform-specific expression patterns and different regulatory 
mechanisms. ACs play an important role in transmembrane signaling events of the G 
protein-coupled receptor (GPCR) cascade and catalyze the conversion from ATP to 
the second messenger cAMP. Activation of these effector proteins transfers signals 
from receptors on the cell surface to target molecules inside the cell and contributes 
to cross-talks in different cell systems and signaling structures.  
The first part of this thesis characterizes the detailed interactions of forskolin 
and six forskolin analogs with recombinant ACs 1, 2 and 5 and determines their 
effects on isoform-specific AC activity. All seven diterpenes affected the examined 
AC isoforms in a characteristic manner, strongly rendering the pharmacological 
profile. Correlations of the pharmacological parameters of these diterpenes between 
the different AC isoforms showed a distinct isoform-specific profile. Since the amino 
acids exhibiting direct interactions with the diterpenes are highly conserved among 
the AC isoforms, the results of this study indicated a contribution of the structural 
environment around the catalytic core to substrate binding and catalysis. Moreover, 
differential impacts of Mg2+ and Mn2+ were obtained on mAC activation by diterpenes. 
However, the metal cofactors showed only low impact on the efficacies of forskolin 
and its analogs of the purified C1/C2 catalytic subunit plus GSα-GTPγS. Additionally, 
docking of diterpenes to the C1/C2 mAC protein did not offer metal ion-dependent 
changes in the docking preferences. Since only small global and local differences 
between the arrangements of Mg2+ and Mn2+ complexes are obtained, the currently 
available docking results are not conclusive to solve the impact of the cofactors on 
AC regulation. Although there are substantial differences in the activity of mAC 
isoforms, due to differential regulation by metal ions, the biological significance of 
Mn2+ in the regulation of substrate binding and catalyzing cAMP production remains 
unclear.  
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The second part describes a biochemical approach to characterize AC in renal 
cortical and medullary membranes in comparison to selected recombinant AC 
isoforms. Considering the paucity of selective and sensitive AC isoform antibodies, 
the characterization of the renal AC isoforms was performed using a biochemical 
approach. Analysis of GPCR agonist-mediated, Ca2+-dependent or calmodulin-
sensitive cAMP formation were used to differentiate between the AC types in the two 
main parts of the kidney. The effects of various hormones and neurotransmitters on 
cortical and medullary ACs detected a tissue-specific distribution of GPCRs and 
subsequently a distinct regulation of tubular functions. The inhibition of cortical and 
medullary ACs by eight 2’(3’)-O-(N-methylanthraniloyl) (MANT)-nucleoside 5’-([γ-
thio])triphosphates yielded characteristic rank orders of pharmacological parameters 
for each part of the kidney. In combination with the inhibition patterns of Ca2+ on 
recombinant ACs 1, 2 and 5 and both renal parts, the classification of the 
predominant cortical AC isoform as AC type 5 was possible. In the case of medulla, 
the pharmacological profiles resembled AC isoform 1. The identification of a major 
AC isoform with biochemical approaches failed, because medullary AC missed the 
characteristic calmodulin-dependency of AC1. However, the predominance of ACs 1, 
2 and 5 could be excluded. Therefore, another isoform − different from type 1, but 
with similar pharmacological characteristics − seemed to play a crucial role in the 
medulla. This identification of the prevalent AC isoform provides the basis for 
exploring ACs as target for the treatment of PKD.  
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D.2 Zusammenfassung 
Adenylylcyclasen (mACs) von Säugetieren sind integrale Membranproteine, 
die an diversen physiologischen Prozessen beteiligt sind. Beispielsweise regulieren 
sie die Kontraktilität des Herzens und die Nierenfunktion. Enzymdefekte oder 
abnormale Regulationen der mAC Isoformen verursachen zahlreiche 
Krankheitszustände wie Herzinsuffizienz, polycystische Nierenerkrankung (PKD), 
neurodegenerative Erkrankungen oder Schmerzzustände und Sucht. Während der 
letzten Jahrzehnte wurden neun verschiedene membrangebundene AC Isoformen in 
Säugetieren entdeckt. Diese werden charakterisiert durch isoform-spezifische 
Gewebeexpression und unterschiedliche Regulationsmechanismen. ACs spielen 
eine wichtige Rolle in transmembranären Signaltransduktionswegen vermittelt durch 
G Protein-gekoppelte Rezeptoren (GPCRs) und katalysieren die Umwandlung von 
ATP in den sekundären Botenstoff cAMP. Die Aktivierung dieser Effektorproteine 
leiten Signale von Rezeptoren auf der Zelloberfläche weiter zu Zielstrukturen im 
Inneren der Zelle. Dadurch tragen sie zur Verständigung zwischen verschiedenen 
Zellsystemen und Signalstrukturen bei.  
Der erste Teil dieser Doktorarbeit charakterisiert die Interaktionen von 
Forskolin und sechs Forskolin-Analoga mit den rekombinanten AC Isoformen 1, 2 
und 5 und untersucht deren Effekte auf die AC Aktivität der einzelnen Subtypen. Alle 
sieben Diterpene beeinflussten die Enzymaktivität der untersuchten mAC Isoformen 
auf charakteristische Weise und gaben dadurch das pharmakologische Profil wieder. 
Korrelationen der pharmakologischen Parameter der Diterpene mit den 
unterschiedlichen mACs zeigten ein individuelles Profil für jede AC Isoform. Da die 
Aminosäuren, die an der Forskolin-Bindung direkt beteiligt sind, unter den AC 
Isoformen stark konserviert sind, deuteten die Ergebnisse dieser Untersuchung auf 
eine Beteiligung der strukturellen Umgebung der katalytischen Tasche an der 
Substratbindung und dem Katalysemechanismus hin. Zusätzlich wurden 
unterschiedliche Auswirkungen von Mg2+ und Mn2+ auf die Diterpen-abhängige 
Aktivität der mACs beobachtet. Die Kofaktoren zeigten jedoch nur unerheblichen 
Einfluss auf den Maximaleffekt von Forskolin und den Analoga auf die gereinigte 
katalytische Einheit C1/C2 plus GSα-GTPγS. Auch das Docking der Diterpene in die 
C1/C2 mAC-Bindetasche bot keine Kofaktor-abhängigen Unterschiede bei den 
Docking-Präferenzen. Da nur geringe allgemeine und lokale Unterschiede zwischen 
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der Anordnung von Mg2+ oder Mn2+ in der Kristallstruktur aufgedeckt wurden, stellt 
das momentan mögliche, molekulare Docking keine beweiskräftige Methode dar, um 
den Einfluss der Kofaktoren auf die AC Regulation zu ergründen. Trotz 
grundlegender Unterschiede in der Aktivität der mAC Isoformen bedingt durch die 
Wahl der Metallionen, ist die biologische Bedeutung von Mn2+ bei der Regulation der 
Substratbindung und der Katalyse unklar.  
Der zweite Teil beschreibt einen biochemischen Ansatz, um die AC Isoformen 
in Cortex- und Medulla-Membranen der Niere im Vergleich mit ausgewählten 
rekombinanten AC Isoformen zu charakterisieren. Aufgrund des Mangels an 
selektiven und sensitiven Antikörpern erfolgte die Charakterisierung der AC 
Isoformen der Niere mit biochemischen Methoden. Durch GPCR-Agonisten 
vermittelte cAMP-Bildung, Ca2+-abhängige AC Aktivierung und die Sensitivität 
gegenüber Calmodulin wurde zwischen den AC Isoformen in den beiden 
Nierenbereichen unterschieden. Die Effekte einiger Hormone und Neurotransmitter 
auf die ACs von Cortex und Medulla zeigten eine gewebsspezifische Verteilung der 
GPCRs und somit eine unterschiedliche Regulation der Tubulusfunktionen. Die 
Hemmung der Nieren-ACs durch acht 2’(3’)-O-(N-methylanthraniloyl) (MANT)-
Nucleosid 5’-([γ-thio])triphosphate erzielten charakteristische Reihenfolgen der 
pharmakologischen Kenngrößen für jeden Teil der Niere. Zusammen mit dem 
Inhibitionsschema mittels Ca2+ an rekombinanten ACs 1, 2 und 5 und beiden 
Nierenbereichen konnte die Identifizierung der vorrangigen AC Isoform des 
Nierencortex als AC5 vorgenommen werden. Bei der Medulla ähnelten die 
pharmakologischen Profile jenen von AC1. Die Identifizierung der Haupt-AC mit 
biochemischen Methoden schlug jedoch fehl, da die medulläre AC Isoform nicht die 
Calmodulin-Abhängigkeit entsprechend der AC1 aufwies. Es konnten allerdings die 
ACs 1, 2 und 5 als vorherrschende Isoformen ausgeschlossen werden. Es scheint 
eine andere Isoform als AC1, aber mit ähnlichem pharmakologischen Profil, die 
Hauptrolle in der Regulation der Medulla zu spielen. Die Identifizierung der 
vorrangigen AC Isoform in der Niere schafft die Grundlage für die Erforschung von 
ACs als Zielstrukturen zur Behandlung der PKD.  
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